 
      
ClinicalTrials.gov ID  [STUDY_ID_REMOVED]  
Sponsor  Inovio Pharmaceuticals  
TITLE: INO-3107 With Electroporation (EP) in Participants With HPV -6- and/ or HPV -11-
Associated Recurrent Respi[INVESTIGATOR_416492] (RRP)  
DATE : [ADDRESS_524891] 2024  
  
CONFIDENTIAL   Page 1 of 61 
  
 
 
 
 
 
 
 
 
 
RRP -001 
 
An open -label multi -center study of INO -3107 with electroporation (EP) in 
subjects with HPV -6- and/or HPV -11-associated recurrent respi[INVESTIGATOR_416493] (RRP)  
 
Sponsored by:  
[CONTACT_416556], Inc.  
 
IND#: [ZIP_CODE]  
 
Protocol Version: 4.0 
Protocol Version Date: 23 July 2021  
RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 2 of 61 
  
Medical Monitor Approval Page  
 
 
Drug:   INO-3107 
 
Sponsor:  Inovio Pharmaceuticals, Inc.  
 660 W. Germantown Pi[INVESTIGATOR_2531], Suite 110  
 Plymouth Meeting, PA [ZIP_CODE]  
 
Medical Monitor:  Jeffrey Skolnik, MD   Senior Vice President, Clinical Development  
 Inovio Pharmaceuticals, Inc.  
 
Approval Signature:  
 
   
[CONTACT_416592], MD  
Senior Vice President, Clinical Development  
Inovio  Pharmaceuticals, Inc.   Date (ddMmmyyyy)  
 
 
 
 
CONFIDENTIAL  
The information in this document is considered privileged and confidential by [CONTACT_416557]. (INOVIO)  and may not be disclosed to others except to the extent 
necessary to obtain Institutional Review Board  (IRB) /Research Ethics Board (REB)/ Ethics 
Committee (EC) approval and informed consent, or as required by [CONTACT_343505]. Persons to whom this information is disclosed must be informed that this 
information is privileged and confidential and that it  should not be further disclosed 
without the written permission of INOVIO . Any supplemental information added to this 
document is also confidential and proprietary information of INOVIO  and must be kept in 
confidence in the same manner as the contents of t his document.  
  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524892]  
(IRB)/Research Ethics Board (REB)/ Ethics Committee  (EC) overseeing the conduct of the  clinical  
trial and approved or given favorable opi[INVESTIGATOR_151580].  
 
The Principal Investigator ’s (PI’s) signature  [CONTACT_416593]’s approval of this Protoc ol and 
provides the necessary assurances that this  clinical  trial will be conducted in accordance with 
International Council for Harmonization ( ICH)/Good Clinical Practice ( GCP ), local legal and 
regulatory requirements, and all stipulations of the Protocol . 
 
 
Principal Investigator [INVESTIGATOR_7496]:  
 
   
Principal Investigator [INVESTIGATOR_416494] (ddMmmyyyy)  
 
 
 
Clinical Trial Site Number:   
Clinical Trial Site Name:   
  
 
  [CONTACT_416594]-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524893]  been edited throughout.  
  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 5 of 61 
 Table of Contents  
Summary of Changes  ................................ ................................ ................................ ................  4 
Clinical Protocol Synopsis  ................................ ................................ ................................ ......... 10 
Schedule of Events  ................................ ................................ ................................ ................... 16 
1.0 Introduction  ................................ ................................ ................................ ................. 17 
1.1 Background and Scientific Rationale: RRP  ................................ ................................ ......17 
1.2 Background Information: DNA and Electroporation with CELLECTRA® 2000  .................. 18 
1.3 Rationale  ................................ ................................ ................................ ......................... 19 
1.4 Potential Benefits and Risks  ................................ ................................ ............................ 19 
2.0 Objectives and Purpose  ................................ ................................ .............................. 21 
2.1 Hypothesis  ................................ ................................ ................................ ....................... 21 
3.0 Clinical Trial Design and Endpoints  ................................ ................................ ............ 21 
3.1 Primary Objective  ................................ ................................ ................................ ............ 22 
3.2 Primary Endpoint  ................................ ................................ ................................ ............. 22 
3.3 Secondary Objective(s)  ................................ ................................ ................................ ...22 
3.4 Secondary Endpoint(s)  ................................ ................................ ................................ ....23 
3.5 Exploratory Objective(s)  ................................ ................................ ................................ ..23 
3.6 Exploratory Endpoint(s)  ................................ ................................ ................................ ...23 
3.7 Ef ficacy Assessment  ................................ ................................ ................................ .......23 
3.8 Safety Assessment  ................................ ................................ ................................ .......... 24 
3.9 Immunogenicity Assessment  ................................ ................................ ........................... 24 
3.10 Virologic Assessment  ................................ ................................ ................................ ....24 
4.0 Clinical Trial Population  ................................ ................................ .............................. 24 
4.1 Inclusion Criteria  ................................ ................................ ................................ .............. 24 
4.2 Exclusion Criteria  ................................ ................................ ................................ ............. 25 
4.3 Discontinuation/Withdrawal of Clinical Trial Subjects  ................................ ....................... [ADDRESS_524894] (IP) and Study Device  ................................ ................................ .27 
5.1.1  INO-3107  ................................ ................................ ................................ ............. 27 
5.1.2      CELLECTRA® 2000  ................................ ................................ ............................. 27 
5.1.3  Side Port Needle  ................................ ................................ ................................ ..27 
5.2  Treatment Regimen  ................................ ................................ ................................ ........ 28 
5.3 Packaging and Labeling  ................................ ................................ ................................ ..28 
5.3.1 INO -3107  ................................ ................................ ................................ .................. 28 
5.3.2 CELLECTRA® 2000 and Side Port Needle  ................................ ................................ 28 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 6 of 61 
 5.4 Handling and Storage  ................................ ................................ ................................ ......28 
5.4.1 INO -3107  ................................ ................................ ................................ .................. 28 
5.4.2 CELLECTRA® 2000  ................................ ................................ ................................ ..29 
5.5 Preparat ion and Dispensing ................................ ................................ ............................. 29 
5.6 Use of Study Device  ................................ ................................ ................................ ........ 29 
5.7 Investigational Drug and Study Device Accountability  ................................ ..................... 29 
5.7.1 INO -3107  ................................ ................................ ................................ .................. 29 
5.7.2 CELLECTRA® 2000 Accountability  ................................ ................................ ............ 29 
5.8 Return and Destruction of Investigational Drug and Study Device  ................................ ...30 
5.8.1 INO -3107  ................................ ................................ ................................ .................. 30 
5.8.2 CELLECTRA® 2000  ................................ ................................ ................................ ..30 
6.0 Clinical Trial Procedures and Schedule  ................................ ................................ ......31 
6.1 Procedure by [CONTACT_4838]  ................................ ................................ ................................ ........... 31 
6.1.1 Clinical Trial Screening Evaluations  ................................ ................................ .......... 31 
[IP_ADDRESS] Medical History  ................................ ................................ ................................ .......32 
[IP_ADDRESS]  Demographics  ................................ ................................ ................................ ......32 
[IP_ADDRESS]  Smok ing History  ................................ ................................ ................................ ...32 
6.1.2  Clinical Trial Evaluations and Procedures  ................................ ............................ 32 
[IP_ADDRESS]  Day 0  ................................ ................................ ................................ ................... 32 
[IP_ADDRESS]  Week 3  ................................ ................................ ................................ ................ 33 
[IP_ADDRESS]  Week 6  ................................ ................................ ................................ ................ 33 
[IP_ADDRESS]  Week 9  ................................ ................................ ................................ ................ 33 
[IP_ADDRESS]  Week 11  ................................ ................................ ................................ .............. 34 
[IP_ADDRESS]  Week 26  ................................ ................................ ................................ .............. 34 
[IP_ADDRESS]  Week 52/End of Study visit  ................................ ................................ .................. [ADDRESS_524895] Identification Numbers  ................................ ............................ 35 
6.4 Safety Evaluations  ................................ ................................ ................................ ......35 
6.4.1  Phys ical Exam and Targeted Physical Assessments  ................................ ........... 35 
6.4.2  Vital Signs  ................................ ................................ ................................ ............ 35 
6.4.3  Height and Weight  ................................ ................................ ............................... 35 
6.4.4  Laboratory Evaluations  ................................ ................................ ........................ 35 
6.4.5 Laryngoscopy and Staging Assessment  ................................ .............................. 36 
6.5 Injection and Electroporation (EP)  ................................ ................................ ............... 37 
6.5.1  Downloading of EP Data from CELLECTRA® 2000 Device  ................................ ..37 
6.6 Management of Anxiety and Pain Due to Electroporation (EP) Procedures  ................ 37 
6.7 Assessment of Laboratory Abnormalities  ................................ ................................ ....37 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 7 of 61 
 6.8 Assessment of Clinical Trial Adverse Event s (AEs) ................................ ..................... 37 
6.9 Assessment of Injection Site Reactions  ................................ ................................ ......37 
6.10  Peripheral Blood Immunogenicity Assessments  ................................ .......................... 38 
6.11  HPV-6/11 testing  ................................ ................................ ................................ ......... 38 
6.12  Tissue Immunogenicity Assessment  ................................ ................................ ........... 38 
6.13  Concomitant Medications/Treatments  ................................ ................................ ......... 39 
6.14  Restrictions  ................................ ................................ ................................ ................. 39 
7 Evaluation of Safety and Management of Toxicity  ................................ ...................... 40 
7.1 Safety Parameters  ................................ ................................ ................................ ......40 
7.2 Adverse Events (AEs)  ................................ ................................ ................................ .40 
7.3 Adverse Drug Reaction (ADR)  ................................ ................................ .................... 40 
7.4 Serious Adverse Events (SAEs)  ................................ ................................ .................. 40 
7.5 Unexpected Adverse Drug Reaction  ................................ ................................ ........... 41 
7.6 Unanticipated (Serious) Adverse Device Effect (UADE)  ................................ .............. 41 
7.7 Device Deficiency  ................................ ................................ ................................ .......42 
7.8 Safety a nd Toxicity Management  ................................ ................................ ................ 42 
7.8.1  Dose Limiting Toxicity (DLT)  ................................ ................................ ................ 42 
7.8.2  Abnormal Laboratory Value  ................................ ................................ ................. 42 
7.8.3  Clinical Trial Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................ 43 
7.9 Safety Data Reporting Period, Method of Collection and Submission  ......................... 43 
7.10  Adverse Event Reporting  ................................ ................................ ............................ 44 
7.10.1  Submitting the Initial Serious Adverse Event (SAE) Report Form  ......................... 44 
7.10.2  Recording the Event  ................................ ................................ ............................ 44 
7.10.3  Assessing Severity (Intensity)  ................................ ................................ .............. 44 
7.10.4  Causal Relationship of Clinical Material to Adverse Events (AEs)  ........................ 44 
7.11  Reporting Pregnancy During the Clinical Trial  ................................ ............................. 45 
7.12  Reporting Device -Related Complaints or Deficiencies  ................................ ................ 46 
7.13  Notifying Regulatory Authorities and Institutiona l Review Boards (IRBs)/Ethics 
Committees (ECs) of Safety Information  ................................ ................................ .....46 
7.13.1  Sponsor Responsibilities  ................................ ................................ ...................... 46 
7.13.2  Principal Investigator (PI) Responsibilities  ................................ ........................... [ADDRESS_524896]-Trial Reporting Requirements  ................................ ................................ ............. 47 
7.15  Clinical Trial Discontinuation  ................................ ................................ ....................... 47 
8 Statistical Considerations  ................................ ................................ ........................... 48 
8.1 Statistical and Analytical Plan  ................................ ................................ ..................... 48 
8.2 General Considerations  ................................ ................................ .............................. 48 
8.3 Statistical Hypotheses  ................................ ................................ ................................ .48 
8.4 Analytical Populations  ................................ ................................ ................................ .48 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 8 of 61 
 8.5 Description of Statistical Methods  ................................ ................................ ............... 48 
8.5.1  Primary Analyses  ................................ ................................ ................................ .48 
8.5.2  Secondary Analyses  ................................ ................................ ............................ 49 
[IP_ADDRESS]    Efficacy  ................................ ................................ ................................ ............... 49 
[IP_ADDRESS]    Immunogenicity  ................................ ................................ ................................ ...49 
8.5.3  Disposition  ................................ ................................ ................................ ........... 50 
8.5.4  Demographi c and Other Baseline Characteristics  ................................ ................ 50 
[IP_ADDRESS]    Demographics  ................................ ................................ ................................ .....50 
[IP_ADDRESS]    Prior medication  ................................ ................................ ................................ ..50 
8.5.5  Interim Analyses  ................................ ................................ ................................ ..50 
8.5.6  Multiplicity  ................................ ................................ ................................ ............ 50 
8.5.7  Missing Values  ................................ ................................ ................................ .....50 
8.5.8  Exploratory Analyses  ................................ ................................ ........................... 51 
[IP_ADDRESS]    Efficacy  ................................ ................................ ................................ ............... 51 
[IP_ADDRESS]    Immunogenicity  ................................ ................................ ................................ ...51 
[IP_ADDRESS]    Concomitant Medic ation  ................................ ................................ ...................... 51 
[IP_ADDRESS]    Vital Signs  ................................ ................................ ................................ ........... 51 
8.6  Sample Size/Power  ................................ ................................ ................................ .....[ADDRESS_524897] (IRB)  ................................ ................................ ................. 52 
9.3 Protection of Human Subjects  ................................ ................................ ..................... 52 
9.3.1  Compliance with Informed Consent Regulations  ................................ .................. 52 
9.3.2  Compliance with IRB Requirements  ................................ ................................ .....52 
9.3.3  Compliance with Good Clinical Practice  ................................ ............................... 53 
9.3.4  Compliance with Electronic Records/Signatures Regulations  .............................. 53 
9.3.5  Compliance with Protocol ................................ ................................ ..................... 53 
9.3.6  Changes to the Protocol  ................................ ................................ ...................... 53 
9.3.7 Vulnerable Subjects  ................................ ................................ ............................. 53 
10 Data Collection, Monitoring and Reporting  ................................ ................................ ..53 
10.1  Confidentiality and Privacy  ................................ ................................ .......................... 53 
11 Source Documents  ................................ ................................ ................................ .....53 
11.1  Records R etention  ................................ ................................ ................................ ......54 
12 Safety and Quality Monitoring  ................................ ................................ ..................... 54 
12.1 Safety Review ................................ ................................ ................................ ................ 54 
12.2 Clinical Monitoring  ................................ ................................ ................................ ......... 55 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524898] of Abbreviations  ................................ ................................ ................................ ...57 
16 References  ................................ ................................ ................................ ................. 59 
 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 10 of 61 
 CLINICAL PROTOCOL SYNOPSIS  
Protocol Title: An open -label multi -center study of INO -3107 with electroporation (EP) in subjects 
with HPV -6- and/or HPV -11-associated recurrent respi[INVESTIGATOR_28617] (RRP)  
Protocol Number:  RRP -001 
Clinical Trial Phase:  1/2 
Estimated Number of Clinical Trial Centers and Countries/Regions:  Approximately 12 sites in the 
US 
Clinical Trial Design:  This is a Phase 1/2 open -label, multicenter trial to evaluate the safety , 
tolerability, immunogenicity , and efficacy  of INO -3107 in subjects with HPV-6 and/or HPV -11- 
associated RRP.  
INO-[ADDRESS_524899] needle, followed by [CONTACT_3450] 
10 subjects who will receive INO -3107 via the Side Port Needle.  
             
This study will enroll approximately  30 adults (≥18 years old) who have been diagnosed with 
either Juvenile -Onset RRP (J -O RRP) as defined by [CONTACT_416558] <12 years  or with Adult -
Onset RRP (A -O RRP) as defined by [CONTACT_416558] ≥[ADDRESS_524900] a safety -run in:  
Up to six subjects  will be enrolled with a one week waiting period between each enrolled  subject .  
Each subject will be assessed up to Week 6. Once the first three subjects of up to these six have 
completed Week 6 assessments, in the absence of dose -limiting toxicity (DLT), subject enrollment 
may begin in full  after review of safety data and discussion between the Sponsor’s Medical 
Monitor and the Investigator (s) at the subjects’ site . However, if prior to the first three  to six  
subjects completing Week  6, a single subject from the first six experiences a DLT then enrollment 
will be limited to six subjects until all six subjects have reached Week [ADDRESS_524901] 6 weeks, enrollment will 
stop, and the Sponsor’s Medical Monitor and Investigator(s) at the subjects’ site(s) will discuss 
the case, and a decision will be made whether to cease further enrollment.  If a change to the 
protocol is required, enrollment will only be r e-initiated after amendment of the protocol and 
approval of the amended protocol by [CONTACT_416559]. 
Enrollment will continue until approximately  30 subjects are enrolled.   
RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524902] six subjects .  If more than two subjects experience a DLT at any time 
during the study , after the initial six subjects ar e enrolled , the Sponsor  will pause enrollment until 
further discussion with the site Investigator determines that the study  may reopen to enrollment.  
Tolerability will be determined by [CONTACT_416560] -limiting toxicity (DLT), which is 
define d as:  
- Treatment -related NCI Common Terminology Criteria for Adverse Events (CTCAE, 
version 5.0) Grade ≥3 non -hematological toxicity that does not respond to supportive 
therapy and lasts for longer than 48 hours , or; 
- Treatment -related NCI CTCAE v5.0 Grade ≥ 3 hematological toxicity that does not respond 
to supportive therapy and lasts for longer than 48 hours.  
Additionally, enrollment and additional dosing will be paused until Sponsor  discussion with the site 
Investigator determines that enrollment and dosing  may continue  if the following CTCAE v5.0 
events are reported at any time in the study:   
• One Grade 4 or 5 related SAE ;  
• Two Grade 3 related SAEs   
Subjects will undergo routine surgical procedure for removal of papi[INVESTIGATOR_81875](s) during the screening 
period within 14 days prior to  Day 0 dosing (papi[INVESTIGATOR_416495] [ADDRESS_524903] been fulfilled).   Biopsy tissue will be collected and sent  to 
 for evaluation of secondary and exploratory endpoints.   Archival tissue (slides 
or blocks) obtained within one year of the screening window may be used , or a biopsy conducted 
during routine surgery .   
Status of disease during the trial will be monitored by [CONTACT_416561] , 
including documentation with Staging Assessment scores.  If at any time during the trial, surgical 
removal (including laser) of papi[INVESTIGATOR_416496], the subject may 
undergo procedure for papi[INVESTIGATOR_416497] , but this must be captured on the electronic case report 
form.   
Documentation of the Staging Assessment score prior to surgery is required, and explanation for 
requirement of surgical removal of papi[INVESTIGATOR_416498].   Surgical interventions during 
the trial must be documented to include information about the appearance and location of tissue 
being removed and instruments used. V ideo/photographic documentation of laryngoscopy is 
required.  
This trial will not utilize a Data Safety Monitoring Board.   This is a single -arm, open -label trial. The 
Sponsor will have access to unblinded safety and tolerability data during the trial . At a minimum, 
the Sponsor’s Medical Monitor will review reported adverse events qu arterly.  
Criteria for Evaluation:   
 
Research Hypothesis : INO -3107,  
 
  delivered intramuscularly (IM) followed by [CONTACT_151638] (EP) with 
CELLECTRA® 2000 will be generally safe  and well-tolerated in subjects with recurrent 
respi[INVESTIGATOR_416499] -6 and/or HPV -11. 
 
Primary Objective : To evaluate the safety  and tolerability of INO-3107  in subjects with HPV-6 
and/or HPV -11- associated RRP .  
 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 12 of 61 
 Primary Endpoint : Safety and tolerability as assessed by [CONTACT_416562] (AE) and 
serious adverse events (SAE) . 
 
Secondary Objective(s):  
1. To evaluate the efficacy of INO -[ADDRESS_524904] , compared to 
the frequency in the year prior to Day 0 . 
2. To evaluate the efficacy of INO-3107  as assessed by [CONTACT_416563].  
3. To evaluate the cellular immune response to  INO-3107 when given IM, followed by [CONTACT_151658].   
4. To evaluate the immunogenicity of INO-3107  as assessed by [CONTACT_23131]-inflammatory and 
immunosuppressive elements in resected tumor tissue at study entry and , if available, 
at subsequent tissue resections . 
5.  
 
 
Secondary Endpoint(s):  
1. Number of RRP surgical interventions in the one year  following Day 0 , compared to the 
one year prior to Day 0 . 
2. Changes in Staging Assessment as measured by [CONTACT_416564].  
3. Antigen -specific cellular immune responses assessed by:  
• IFN-γ secreting cells in peripheral blood mononuclear cells (PBMCs) by [CONTACT_34536]   
• T cell phenotype and lytic potential in PBMCs  by [CONTACT_4133]  
4. Assessment of pro -inflammatory and immunosuppressive elements in resected tumor 
tissue, if available.  
5.  
 
  
  
  
   
  
 
  
 
  
 
  
  
  
  
  
 
  
 
Safety Assessment : Subjects will be followed for safety from the time of signing informed consent 
through Week 52, or the subject’s last visit.  All adverse events including SAEs, UADEs, DLTs 
and other AEs will be recorded. Clinically significant c hanges  in laboratory parameters and vital 
signs  from baseline assessments will be assessed . RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 13 of 61 
 Efficacy  Assessment : A detailed m edical history will be obtained for each subject which will 
include  documentation of HPV -6 and/or HPV -[ADDRESS_524905] two surgical RRP interventions  (including laser) in the year prior to and including 
Day 0,  to be eligible for the trial.  Subjects must require RRP intervention at the time of entry 
into this study  and will undergo routine surgical removal of their papi[INVESTIGATOR_81875](s) during screening , 
within [ADDRESS_524906] Day 0 compared to the number of RRP surgical interventions in the year prior 
to Day 0  dosing .  RRP surgical interventions include laser therapi[INVESTIGATOR_014].   The trial will also evaluate  
changes in RRP Staging Assessment  over time.   
Immunogenicity Assessment : The trial will explore humoral and cell mediated immune responses 
in blood samples taken at baseline (i.e. Screening and Day 0 prior to dosing) and Weeks 6, 9, 11, 
26, and 52. Tissue samples will be collected at baseline and if clinically indic ated during the study. 
 
 
 
Virologic Assessment : The trial will evaluate the presence of HPV -6/11 DNA in tissue samples 
and peripheral blood , prior to and following study treatment, as described . 
Clinical Trial Population : Subjects with HPV -6- and/or HPV -11-associated RRP, who  require  at 
least two surgical interventions  per year for the past year  (minimum),  for removal of associated 
papi[INVESTIGATOR_81875] (s). Approximately 30 adult subjects (aged 18 and older) diagnosed with Juvenile -Onset 
RRP (age at diagnosis <12 years)  or Adult -Onset RRP (age at diagnosis ≥12  years)  will be 
enrolled.  
Inclusion Criteria ; Subjects Must:  
1. Provide written IRB -approved informed consent in accordance with institutional guidelines;  
2. Be ≥18 years of age  on the day of signing the informed consent, and able and willing to 
comply with all  trial procedures;  
3. Have histologically  documented HPV -6- and/or HPV -11-positive respi[INVESTIGATOR_416500] -risk positive HPV using a Sponsor approved HPV -6/11 type -specific 
assay ; 
4. Have a requirement for frequent RRP intervention in order to remove or resect respi[INVESTIGATOR_416501], as defined as at least two RRP surgical (including laser) interventions in the year 
prior to and including Day 0 ; 
5. Must be appropriate candidate for upcoming surgical intervention  per investigator judgement  
and RRP Staging Assessment score (see Section 6.4.5 );  
6. Have adequate bone marrow, hepatic, and renal function as defined by: [CONTACT_58846] (Absolute 
Neutrophil Count) ≥1000 cells/mm3, platelets ≥50,000/mm3, hemoglobin ≥9 g/dL; 
concentrations of total serum bilirubin within 1.5 x upper limit of normal (ULN), AST and ALT 
within 1.[ADDRESS_524907], serum creatinine ≤ 1.[ADDRESS_524908];   
7. Agree that during the trial, male participants  will not father a child, and female parti cipants  
cannot be or become pregnant if they are of child -bearing potential. Subjects must  meet one 
of the below requirements : RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 14 of 61 
 a. Be o f non -childbearing potential (≥12 months of non -therapy -induced amenorrhea, 
confirmed by [CONTACT_9284] [FSH ], if not on hormone replacement);  
b. Be surgically sterile (vasectomy in males or absence of ovaries and/or uterus in females);  
c. Agree to use one highly effective or combined contraceptive methods that result in a failure 
rate of <1% per year during t he treatment period and at least through week [ADDRESS_524909] 
dose. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post -ovulation 
methods) and withdrawal are not acceptable methods of contraception.  
d. Agree to a bstinence from penile -vaginal intercourse , when this is the subject’s preferred 
and usual lifestyle . 
Exclusion Criteri a; Subjects Must Not:  
1. Receive therapy directed towards RRP  disease (other than surgery or ablation) including 
but not limited to anti -virals  (including cidofovir) , radiation, chemotherapy, anti -angiogenic 
therapy  (including bevacizumab) , prophylactic HPV vaccination  (including Gardasil)  as 
therapeutic intervention , or therapy with an experimental agent within 3 months  prior to 
Day 0;  
2. Have ongo ing or recent (within one year) evidence of autoimmune disease that required 
treatment with systemic immunosuppressive treatments, with the exception of: vitiligo, 
childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism that requires 
only hormone replacement, or psoriasis that does not require systemic treatment;  
3. Have a diagnosis of immunodeficiency or treatment with systemic immunosuppressive 
therapy within [ADDRESS_524910] dose of trial treatment, including systemic 
corticos teroids;  
4. Have a high risk of bleeding or r equire the use of anti -coagulants for management of a 
known bleeding diathesis;  
5. Receive any live virus vaccine within [ADDRESS_524911] dose of trial treatment ; 
6. Have a history of clinically significant, medically unstable disease which, in the judgment 
of the Investigator, would jeopardize the safety of the subject, interfere wit h trial 
assessments or endpoint evaluation, or otherwise impact the validity of the trial results.  
This may include chronic renal failure; myocardial ischemia or infarction; [LOCATION_001] Heart 
Association (NYHA) class III/ IV cardiac disease); any cardiac pre -excitation syndromes 
(such as Wolff -Parkinson -White; cardiomyopathy, or clinically significant arrhythmias); 
current malignancy with the exception of treated basal or squamous cell skin cancers, 
prostate cancer, or carcinoma of the cervix in situ; HIV, wh ich may impact the ability to 
mount an immune response to the study therapy; or drug or alcohol dependence;  
7. Have fewer than two acceptable sites available for IM injection considering the deltoid and 
anterolateral quadriceps muscles. The following are unac ceptable sites:  
a. Tattoos, keloids or hypertrophic scars located within 2 cm of intended treatment 
site; 
b. Cardioverter -defibrillator or pacemaker (to prevent a life -threatening arrhythmia) 
that is located ipsilateral to the deltoid injection site (unless deemed acceptable by 
a cardiologist);  
c. Metal implants or implantable medical device within the intended treatment site;  
8. Be imprisoned, or compulsory detainment (involuntary incarceration) for treatment of 
either a psychiatric or physical (i.e. infectious di sease) illness;  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 15 of 61 
 9. Be pregnant or current ly breastfeeding;  
10. As determined by [CONTACT_737], have any medical or psychological or non -medical 
condition that might interfere with the subject’s ability to participate or affect the safety of 
the subject.  
Clinical Trial Treatment:   
Subjects  will receive a 1  mL injection of INO -3107 IM followed by [CONTACT_151658].  Doses will be administered 
at Day 0, Week s 3, 6, and 9. 
 
 
Device: CELLECTRA® 2000 . 
  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 16 of 61 
 SCHEDULE OF EVENTS  
Schedule of Events  
 
Screening  
Day 0  
Week 3 (±4 days)  
Week 6 (±4 days)  
Week 9 (±4 days)  
Week 11 (±1 week)  
Week 26 (±2 week)  
Week 52 /End of study (±2 
weeks) 
Informed consent X        
Medical history , smoking history  X        
Inclusion/Exclusion criteria  X X       
Demographics  X        
Concomitant medications, AEs  X X X X X X X X 
Physical exama X X X X X  X X 
Vital signs  X X X X X  X X 
Height, weight, BMI  X X X X    
Safety labsb X X X X X    
Pregnancy test, if applicablec X X X X X    
INO-3107   X X X X    
Immunology samples  X X  X X X X X 
Virology sampled  X  X  X X X 
Laryngoscopy and Staging 
assessmente Xf   X  X X X 
Tissue sampleg X       X 
 
 
a. Full physical examination (PE) mandatory at screening and study discharge ( Week 52/End of Study visit  or 
relapse), otherwise targeted physical assessment as determined by [CONTACT_416565] . 
b. Collected within [ADDRESS_524912] is req uired prior to each study treatment . 
d.  
e. Staging assessment to be performed during each laryngoscopy and prior to any RRP intervention using the 
RRP Staging Assessment tool.  Video/photographic documentation of laryngoscopy is required.    
f. Staging to be performed prior to Routine RRP intervention at Screening, followed by [CONTACT_416566] 14 days.  
g. Biopsy t issue should be sent for HPV typi[INVESTIGATOR_416502], Week 52, and at any 
tissue resection, if applicable.  Archival tissue collected within 1 year of Day 0 may be sent at screening .  Biopsy 
required with laryngoscopy at Week 52.   RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 17 of 61 
 1.0 INTRODUCTION  
1.1 BACKGROUND AND SCIENTIFIC RATIONALE : RRP  
Human papi[INVESTIGATOR_27509] (HPV) -associa ted malignancies are an emerging global epi[INVESTIGATOR_901] 
[1]. The role of HPV -6 and -11 in the etiology of recurrent respi[INVESTIGATOR_416503] ( RRP) , 
the most common benign tumor (s) of the laryngeal epi[INVESTIGATOR_2130] , is well -established  [2, 3]. 
RRP is rare, with an incidences estimated at 1.8 per 100,000 adults in the [LOCATION_002]  
[4], and age of diagnosis ranging from young children to older adults . Although most lesions 
are benign, some undergo malignant transformation, and patients with RRP have a higher 
risk of developi[INVESTIGATOR_416504] [5].  
 
HPV-[ADDRESS_524913] , etc [6]. Rarely , malignant transformation may occur, which is usually 
associated with a dismal prognosis. A few such patients with malignant disease may be 
candida tes for salvage therapi[INVESTIGATOR_014], including potentially definitive surgery  [7, 8]. Selected 
patients in this setting may benefit from radiation although the morbidity of this approach 
is subst antial [8]. Recently, a Phase 2  study of pembrolizumab in patients  with RRP 
demonstrated a response rate of 43%,  and this observation supports a rationale for 
immunotherapeutic management of RRP [9]. 
 
Current treatment of HPV -6- and HPV -11-related RRP could potentially be improved or 
replaced with the addition of HPV -specific immunotherapy. Available preventive HPV 
vaccines can generate neutralizing antibodies against the HPV major capsid protein L1, 
but they have not demonstrated therapeutic effects on HPV infection or existing les ions, 
and are unlikely to engender a cytolytic T -cell response  [10]. HPV -specific immunotherapy 
targeting E6 and E7 proteins, on the other hand , may have therapeutic potential to 
eliminate preexisting lesions and infections by [CONTACT_416567]. HPV E6 and E7 oncoproteins represent ideal targets for this 
type of therapeutic intervention becaus e of their constitutive expression in HPV associated 
tumors and their crucial role in the induction and maintenance of HPV associated diseases  
[10]. 
 
Preclinical studies of INO -3106, a synthetic DNA plasmid encoding  versions of the E6 and 
E7 proteins of HPV -6, have  demonstrated strong and specific immune response in animal 
models  [10]. HPV -16/18 -specific therapy (VGX -3100) designed and evaluated based on the 
same synthetic consensus platform, has demonstrated cellular immune responses that 
correlated with c linical benefit in the form of dysplastic lesion regression and elimination 
of HPV -16/18 infection in  a Phase 2 study, and now support late -phase ongoing clinical 
trials targeting HPV -16 and HPV-18 associated diseases [11].   
 
A pi[INVESTIGATOR_416505] -6-asso ciated 
papi[INVESTIGATOR_28602] (HPV -006), treated with INO -3106, and was deemed tolerable.  
Importantly, INO -[ADDRESS_524914] HPV -6 E6 and 
E7 proteins,  and evidence of clinical benefit , in two of the three patients treated .  Two 
patients with RRP who previously required every six -month debridement of their RRP RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524915] ; one patient sustaining a 
surgery -free interval for over 900 days, and another for over 500 days, following therapy 
with INO -3106 on -study  [12].  Following on this study, Inovio is conducting a study of INO -
3107, comprised of a single plasmid that encodes for both HPV -6 and HPV -11 E6 an E7 
proteins, plus a single plasmid that encodes for IL -12.  Inovio is conducting this study in 
adults  with RRP who are at risk o f requiring additional and continuous surgery to manage 
their disease.   It is hypothesized that INO -3107 will be safe, tolerable, immunogenic and 
efficacious in the treatment of patients  with HPV -6 and/or HPV -11-associated RRP.  
1.2 BACKGROUND INFORMATION : DNA  AND ELECTROPORATION WITH CELLECTRA® 
2000  
Synthetic DNA  (sDNA) represents a novel  approach for immunotherapy, and offers 
several potential advantages  over current immunotherapi[INVESTIGATOR_014]  [13]. First, potent T -cell 
immune responses can be generated to virtually any antigenic sequence. Second , sDNA -
based  therapi[INVESTIGATOR_416506] a 
virulent form as opposed to viral - or bacterial -based vaccines, which may mutate back to 
a virulent form or spread to unintended individuals. Toxicology studies have found no 
evidence of genome integration  from sDNA vaccines [14, 15]. Third, repeated dosing of 
sDNA  therapi[INVESTIGATOR_416507] , resulting in  decreased or no immun ogenicity  from 
these viral -based vaccines . Thus , sDNA therapy  allow s repeated dosing (or boosting) to 
potentially increase or maintain immunogenicity  over long periods  of time . Finally, sDNA 
therapi[INVESTIGATOR_416508] -stable for long periods of time.  Prior  work  by [CONTACT_416568]-specific therapy has demonstrat ed promising preliminar y results that  support  late-
phase clinical trials targeting HPV 16 and 18 associated diseases  and cancers  [11]. 
 
This study will utilize Inovio’s INO -[ADDRESS_524916] shown that the immunogenicity of DNA therapi[INVESTIGATOR_416509] [16-20]. Importantly, the concomitant 
injection of a plasmid encoding for the human  IL-12 cytokine  has been shown to enhance 
sDNA therapy -mediated immunogenicity in humans whe n delivered using the 
CELLECTRA® 2000 EP device [21, 22]. We have established in multiple clinical studies 
targeting both IM and intraderm al (ID) delivery that sDNA delivered with  the CELLECTRA® 
2000 device is a reproducible method of generating immunity in human s for various 
potential clinical indications  ranging from  the treatment of cancer to the  induction  of 
pathogen prophylaxis  [1, 11, 2 1-27].   
 
Electroporation has repeatedly  shown to be an efficient way to introduce DNA into cells 
[28, 29]. The mechanism of EP is to create a transient electric field that induces temporary 
and reversible pores in the cell membrane, allowing DNA plasmids to enter the cells. This 
technology has been used for  more than three decades by [CONTACT_416569],  EP remains experimental in the clinic. 
Clinical applications of EP have been tested in treatment of cancer and for gene therapy 
[30-32]. The CELLECTRA® 2000 EP device to be used in this study has been used in several 
clinical trials, demonstrating a tolerable  safety prolife and improved efficacy of DNA 
transfection (see Section 1.4).  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 19 of 61 
  
 
 
 
  
 
 
 
 
 
 
 
  
 
This clinic al trial will be conducted in compliance with the clinical study protocol, Good 
Clinical Practice, and applicable regulatory requirements.  
1.3 RATIONALE  
Inovio’s sDNA therapy VGX -3100 has demonstrated tolerability, immunogenicity and 
efficacy in a randomized Phase 2b study in HPV -16/18 pre -malignant disease of the 
cervix, and a pi[INVESTIGATOR_416510] -3106 with INO -9012 in three patients with HPV -6-related 
aerodigestive disease which demonstrated tolerability, immunogenicity and preliminary 
efficacy, spe cifically in two patients with RRP.  RRP, although rare, continues to be 
diagnosed in adults and adolescents, and in children.  Therapeutic treatment consists of  
frequent ly recurring  surgery, and t here are few other therapi[INVESTIGATOR_416511].  
Historical or o ngoing clinical studies include evaluating anti -virals (cidofovir), angiogenesis 
inhibitors (bevacizumab), and checkpoint inhibitors (pembrolizumab, others), and those 
have shown some promising results  [2].  However , no product has been labeled  for RRP.  
INO-[ADDRESS_524917] dose . 
1.4 POTENTIAL BENEFITS AND RISKS 
INO-3107 has the potential to treat patients  with HPV -6 and/or HPV -11-associated RRP, 
reducing the number of surgical  interventions required to control the disease, and 
potentially to eradicate the virus in treated patients, potentially resulting in a disease cure.  
This not only would reduce exposure to future inevitable surgical intervention but would 
also remove the signs and symptoms associated with RRP  and the potential for malignant 
transformation and development of HPV -6- or HPV -11-associated cancer.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524918] been well  described and are coupled with 
the risks of EP with the CELLEC TRA® [ADDRESS_524919] received injections with the Inovio platform utilizing 
the CELLECTRA® 2000 device  to date .  In general , the risks associated with DNA therapy 
and the CELLECTRA® 2000 device are limited to localized injection reactions, including 
injection site pain, erythema, edema or bruising; fever, fatigue, headache , myalgia , and 
arthralgia  have also been reported.  Pain associated with the CELLECTRA® device has 
been well -characterize d and is largely transient  [33].  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 21 of 61 
 2.0 OBJECTIVES AND PURPOSE  
This is a Phase 1/2 open -label, multicenter trial to evaluate the safety , tolerability, 
immunogenicity , and efficacy  of INO -3107 in subjects with RRP.  
2.1 HYPOTHESIS  
INO-3107,  
 
delivered intramuscularly (IM) followed by [CONTACT_151638] (EP) with CELLECTRA® 2000 
will be generally safe and well-tolerated in subjects with recurrent respi[INVESTIGATOR_416512] -6 and/or HPV -11. 
3.0 CLINICAL TRIAL DESIGN AND ENDPOINTS  
This is a Phase 1/[ADDRESS_524920] needle, followed by  [CONTACT_3450] 10 
subjects who will receive INO -3107 via the Side Port Needle.  
This trial will enroll approximately 30 adults ( ≥18 years old) who have been diagnosed 
with either Juvenile -Onset RRP (J -O RRP) as defined by [CONTACT_416558] <12 years  
or Adult -Onset RRP (A -O RRP) as defined by [CONTACT_416558] ≥[ADDRESS_524921] a safety -run in:  
Up to six , subjects will be enrolled with a one week waiting period between e ach enrolled 
subject .  Each subject will be assessed up to Week 6. Once the first three subjects  of up 
to these six have completed Week 6 assessments, in the absence of dose -limiting 
toxicity (DLT), subject enrollment may begin in full  after review of safety date and 
discussion between the Sponsor’s Medical Monitor and the Investigator’s at the subje cts’ 
site. However, if prior to the first three to six subjects completing Week 6, a single subject 
from the first six experiences a DLT then enrollment will be limited to six subjects until 
all six subjects have reached Week [ADDRESS_524922] 6 weeks, 
enrollment will stop, and the Sponsor’s Medical Monitor and Investigator(s) at the 
subjects’ site(s) will discuss the case, and a decision will be made whether to cease 
furthe r enrollment. If a change to the protocol is required, enrollment will only be re -
initiated after amendment of the protocol and approval of the amended protocol by [CONTACT_416570]. 
Enrollment will continue until approximately  [ADDRESS_524923] six subjects.  If more than two subjects experience a 
DLT at any time during the study, after the initia l six subjects are enrolled,  the Sponsor  
will pause enrollment until further discussion with the site Investigator determines that 
the study may reopen to enrollment.  
Tolerability will be determined by [CONTACT_416560] -limiting toxicity (DLT) , 
which is defined as:  
o Treatment -related NCI Common Terminology Criteria for Adverse Events 
(CTCAE, version 5.0) Grade ≥3 non -hematological toxicity that does not respond 
to supportive therapy and lasts for longer than 48 hours , or; RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 22 of 61 
 o Treatment -related NCI CTCAE v5.0 Grade ≥ 3 hematological toxicity that does 
not respond to supportive therapy and lasts for longer than 48 hours.  
Additionally, enrollment and additional dosing will be paused until Sponsor discussion 
with the site Investigator determines that enr ollment and dosing may continue, if the 
following CTCAE v5.0 events occur  at any time in the study:  
• One Grade 4 or 5 related SAE;  
• Two Grade 3 related SAEs  
Subjects will undergo routine surgical procedure for removal of papi[INVESTIGATOR_81875](s) during the 
screening period within 14 days prior to  Day 0 dosing (papi[INVESTIGATOR_416495] [ADDRESS_524924] been fulfilled).  Biopsy 
tissue will be collected and sent to  for evaluation of secondary and 
exploratory endpoints.  Archival tissue (slides or blocks) obtained within one year of the 
screening window may be used , or a biopsy conducted during routine sur gery.  
Status of d isease during the trial will be monitored by [CONTACT_416571].  If at any time 
during the trial, surgical removal (including laser) of papi[INVESTIGATOR_416513], the subject may undergo procedure for papi[INVESTIGATOR_416514] .  Documentation of the Staging 
Assessment score prior to surgery is required, and explanation for requirement of 
surgical removal of papi[INVESTIGATOR_416498].  
Surgical interventions during the trial must be documented to include at a minimum, 
information about the appearance  and location of tissue being removed and instruments 
used. Video/photographic documentation of laryngoscopy is required.  
This trial will not utilize a Data Safety Monitoring Board.  This is a single -arm, open -label 
trial. The Sponsor will have access to unblinded safety and tolerability data during the 
trial. At a minimum, the Sponsor’s Medical M onitor will review reported adverse events 
quarterly.  
3.1 PRIMARY OBJECTIVE  
To evaluate the safety  and tolerability  of INO-3107  in subjects with HPV-6 and/or HPV -
11- associated RRP . 
3.2 PRIMARY ENDPOINT  
Safety and tolerability as assessed by [CONTACT_416562] (AE) and serious adverse 
events (SAE) . 
3.3 SECONDARY OBJECTIVE (S) 
1. To evaluate the efficacy of INO -[ADDRESS_524925] , 
compared to  the frequency in the year prior to Day 0 . 
2. To evaluate the efficacy of INO -3107 as assessed by [CONTACT_416563].  
3. To evaluate the cellular immune response to INO -3107 when given IM, followed 
by [CONTACT_151658].  
4. To evaluate the immunogenic ity of INO -3107 as assessed by [CONTACT_23131] -inflammatory 
and immunosuppressive elements in resected tumor tissue at study entry and , if 
available, at subsequent tissue resections . RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 23 of 61 
 5.  
 
3.4 SECONDARY ENDPOINT (S) 
1. Number of RRP surgical interventions in the one year following Day 0, compared 
to the one year prior to Day 0. 
2. Changes in Staging Assessment as measured by [CONTACT_416572].  
3. Antigen -specific cellular immune responses assessed by:  
• IFN-γ secreting cells in peripheral blood mononuclear cells (PBMCs) by 
[CONTACT_34536]   
• T cell phenotype and lytic potential in PBMCs  by [CONTACT_4133]  
4. Assessment of pro -inflammatory and immunosuppressive elements in resected 
tumor tissue, if available.  
5.  
 
  
  
 
  
  
  
 
  
 
  
  
  
  
  
 
  
 
          
 
3.[ADDRESS_524926] which will include 
documentation of HPV -6 and/or HPV -[ADDRESS_524927] two surgical RRP int erventions  (including laser) in the year 
prior to and including Day 0,  to be eligible for the study.  Subjects must require RRP 
intervention at the time of entry into this study and  will undergo surgical removal of 
their papi[INVESTIGATOR_81875](s) during screening, with in [ADDRESS_524928] Day 0 compared to the number of RRP surgical interventions in RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524929]’s last visit.  All adverse events including SAEs, UADEs, and DLTs. 
Clinically significant c hanges  in laboratory parameters and vital signs  from baseline 
assessments will be assessed .  
3.9 IMMUNOGENICITY ASSESSMENT  
 
 
 
            
 
 
3.10  VIROLOGIC ASSESSMENT  
The trial will evaluate the presence of HPV -6/11 DNA in tissue samples and peripheral 
blood , prior to and following study treatment, as described .  
4.0 CLINICAL TRIAL POPULATION  
4.1 INCLUSION CRITERIA  
1. Provide written IRB -approved informed consent in accordance with institutional 
guidelines;  
2. Be ≥18 years  of age on the day of signing the informed cons ent, and able and willing 
to comply with all trial procedures;  
3. Have histologically  document ed HPV -6- or HPV -11-positive respi[INVESTIGATOR_416500] -risk positive HPV using a Sponsor approved HPV -6/11 type -
specific assay ; 
4. Have a requirement for frequent RRP intervention in order to remove or resect 
respi[INVESTIGATOR_416515], as defi ned as at least two RRP surgical (including laser) 
interventions in the year prior to and including Day 0 ; 
5. Must be appropriate candidate for upcoming surgical intervention  per investigator 
judgement and RRP Staging Assessment score ( see Section 6.4.5 );  
6.  Have adequate bone marrow, hepatic, and renal function as defined by: [CONTACT_58846] 
(Absolute Neutrophil Count) ≥1000 cells/mm3, platelets ≥50,000/mm3, hemoglobin ≥9 
g/dL; concentrations of total serum bilirubin within 1.5 x upper limit of normal (ULN), 
AST and  ALT within 1.[ADDRESS_524930], serum creatinine ≤ 1.[ADDRESS_524931];  
7. Agree that during the trial, male participants  will not father a child, and female 
participants  cannot be or become pregnant if they are of child -bearing potential. 
Subjects must  meet one of the below requirements : RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 25 of 61 
 a.  Be o f non -childbearing potential (≥12 months of non -therapy -induced 
amenorrhea, confirmed by [CONTACT_9284] [FSH], if not on hormone 
replacement;  
b.  Be surgically sterile (vasectomy in males or absence of ovaries and/or uterus in 
females);  
c.  Agree to use one highly effective or combined contraceptive methods that result 
in a failure rate of <1% per year during the treatment period and at least through 
week [ADDRESS_524932] dose. Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, or post -ovulation methods) and withdrawal are not acceptable 
methods of contraception.  
d.  Agree to a bstinence from penile -vaginal intercourse , when this is the subject ’s 
preferred and usual lifestyle . 
4.[ADDRESS_524933] Not:  
1. Receive therapy directed towards RRP  disease (other than surgery or ablation) 
including but not limited to anti -virals  (including cidofovir) , radiation, chemotherapy, 
anti-angiogen ic therapy (including bevacizumab), prophylactic HPV  vaccination 
(including Gardasil)  as therapeutic intervention , or therapy with an experimental agent 
within 3 months  prior to Day 0;  
2. Have ongoing or recent (within one year) evidence of autoimmune disease  that 
required treatment with systemic immunosuppressive treatments, with the exception 
of: vitiligo, childhood asthma that has resolved, type 1 diabetes, residual 
hypothyroidism that requires only hormone replacement, or psoriasis that does not 
require sy stemic treatment;  
3. Have a diagnosis of immunodeficiency or treatment with systemic immunosuppressive 
therapy within [ADDRESS_524934] dose of trial treatment, including systemic 
corticosteroids;  
4. Have a high risk of bleeding or require the use of anti-coagulants for management of 
a known bleeding diathesis;   
5. Receive any live virus vaccine within [ADDRESS_524935] dose of trial treatment ; 
6. Have a history of clini cally significant, medically unstable disease which, in the 
judgment of the Investigator, would jeopardize the safety of the subject, interfere with 
trial assessments or endpoint evaluation, or otherwise impact the validity of the trial 
results.  This may include chronic renal failure; myocardial ischemia or infarction; New 
York Heart Association (NYHA) class III/ IV cardiac disease); any cardiac pre -
excitation syndromes (such as Wolff -Parkinson -White; cardiomyopathy, or clinically 
significant arrhythmias);  current malignancy with the exception of treated basal or 
squamous cell skin cancers, prostate cancer, or carcinoma of the cervix in situ; HIV, 
which may impact the ability to mount an immune response to the study therapy; or 
drug or alcohol dependence;  
7. Have fewer than two acceptable sites available for IM injection considering the deltoid 
and anterolateral quadriceps muscles. The following are unacceptable sites:  
a. Tattoos, keloids or hypertrophic scars located within 2 cm of intended treatment 
site; RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 26 of 61 
 b. Cardioverter -defibrillator or pacemaker (to prevent a life -threatening arrhythmia) 
that is located ipsilateral to the deltoid injection site (unless deemed acceptable by 
a cardiologist);  
c. Metal implants or implantable medical device within the intended trea tment site;  
8. Be imprisoned, or compulsory detainment (involuntary incarceration) for treatment of 
either a psychiatric or physical (i.e. infectious disease) illness;  
9. Be pregnant or current breastfeeding;  
10. As determined by [CONTACT_737], have any medical o r psychological or non -medical 
condition that might interfere with the subject’s ability to participate or affect the safety 
of the subject.  
4.3 DISCONTINUATION /WITHDRAWAL OF  CLINICAL  TRIAL SUBJECTS  
A subject will be considered to have completed the trial when the subject has completed 
all study visits through Week 52.  Subjects may withdraw consent at any time for any 
reason or be dropped from the trial at the discretion of the Investigator should any 
untoward effect occur.  In addition, the  Investigator o r the Sponsor has the right to 
discontinue  a subject from the trial at any time.  
The Investigator must notify the Sponsor within [ADDRESS_524936] has been 
discontinued/withdrawn due to an Adverse Event (AE). Any AEs and/or SAEs present at 
the time o f discontinuation/withdrawal should be followed in accordance with the safety 
requirements outlined in section 7.1: Safety Parameters.   
4.3.[ADDRESS_524937] (IP) if any of the 
following occur:  
• Subject withdrawal of consent or subject is lost to follow up  
• An AE that, in the opi[INVESTIGATOR_303793], contraindicates further 
dosing of any trial medication  
• Pregnancy  
• Subject non -compliance  that, in the opi[INVESTIGATOR_12182], warrants 
discontinuation  
• Initiation of new contraindicated therapy  
In the absence of any of the above criterion, if limited clinical benefit is suspected at any 
time, IP may be discontinued after consul tation between the Investigator and the Medical 
Monitor.    
4.3.[ADDRESS_524938] all scheduled immune 
assessment blood samples collected as indicated in the Schedule of Events (Table 1). At 
a minimum, the Investigator should request to have the subject complete the End of Study 
visit assessments as indicated in the schedule of events at the subject’s final visit.       RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524939] 
label provided in the Investigator ’s Brochure  (IB).  All subjects will receive active INO -
3107.   
5.3.2  CELLECTRA® 2000  AND SIDE PORT NEEDLE  
Please see shippi[INVESTIGATOR_416516], and unpacking 
instructions.  
The CELLECTRA® [ADDRESS_524940] of business of the manufacturer. The CELLECTRA® 2000 User Manual 
describes all relevant contraindications, hazards, potential risks and adverse effects, 
interfering substances or devices, warnings, and prec autions. The CELLECTRA® 2000 
Pulse Generator and IM Applicator ha ve unique serial number s. Each IM Array has a Lot 
Number and Expi[INVESTIGATOR_5952]. Examples of device labels are provided in the Investigator’s 
Brochure  (IB). 
The CELLECTRA® 2000 device and its co mponents will be shipped directly from the 
manufacturer to the study site.  
Side Port Needles will be provided to the study site and are packaged with the 
CELLECTRA® 2000 IM Array in a sterile enclosure.  
5.4 HANDLING AND STORAGE  
5.4.1  INO-3107  
   
 
 
 
 
 
 
 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 29 of 61 
 5.4.2  CELLECTRA® 2000  
See User Manual for operating and storage conditions.  
5.5 PREPARATION AND DISPENSING  
  
INO-3107  will be provided to the investigational pharmacy in vial form directly from the 
manufacturing facility or designee.   It is the responsibility of the Investigator to ensure that 
INO-3107  is only dispensed to study subjects.   
 
 
   
  
 
 
 
 
Detailed instructio ns on handling and dispensing of INO-3107  are provided in the 
Pharmacy Manual .  
5.6 USE OF STUDY  DEVICE  
The instructions for use of the CELLECTRA® 2000 device is provided in the User Manual. 
Each clinical site will receive training for use of the CELLECTRA® [ADDRESS_524941] 
comply with applicable regulations and guidelines . The accountability information is 
provided in the Pharmacy Manual.  
5.7.2  CELLECTRA® [ADDRESS_524942] and then disposed RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524943] be 
discarded after use in accordance with institutional policy for disposal of sharp 
needles/instruments.  
Site personnel will be requested  to down load EP data and provide to Inovio after each 
treatment.  
5.8 RETURN AND DESTRUCTION OF INVESTIGATIONAL  DRUG AND STUDY DEVICE  
5.8.1  INO-3107  
Upon completion or termination of the study, all unused and/or partially use d IP must be 
destroyed at site per insti tution policy or returned to Inovio Pharmaceuticals, Inc. or its 
designee, if site cannot destroy IP.  If IP is to be destroyed on site, it is the Investigator' s 
responsibility to ensure that arrangements have been made for the disposal, written 
authorizati on has been granted by [CONTACT_343423], Inc., or its designee, 
procedures for proper disposal have been established according to applicable regulation 
and guidelines and institutional procedures, and appropriate records of the disposal have 
been doc umented. Reconciliation of any unused IP must  be performed  and provided to  
the responsible Inovio Pharmaceuticals, Inc. or designated Study Monitor  for review prior 
to on -site destruction . 
The used IP vials will be discarded per site’s used IP disposal pro cedure. It is the 
Investigator’s responsibility to arrange for disposal of all empty vials, provided that 
procedures for proper disposal have been established according to applicable federal, 
state, local and institutional guidelines and procedures, and pr ovided that appropriate 
records of disposal are kept.  
If requested by [CONTACT_1034], the return of unused IP should be arranged by [CONTACT_416573] . All IP returned to Inovio Pharmaceuticals, Inc., or its designee, must be 
accompanied by [CONTACT_76764]. Returned supplies should be in the 
original containers. Empty containers should not be returned to Inovio Pharmaceuticals, 
Inc. 
5.8.2  CELLE CTRA® 2000   
Upon completion or termination of dosing , an Inovio Representative will provide 
instructions regarding the component(s) to be returned to Inovio Pharmaceuticals, Inc., 
destroyed onsite or shipped to a destruction vendor.  
All product returned to  Inovio Pharmaceuticals Inc. must be accompanied by [CONTACT_343623]. Returned supplies should be in the original containers. 
The return of all product identified above should be arranged by [CONTACT_416574]. 
Used  IM Arrays sho uld be discarded in the sharp’s  container immediately after use. The 
used IM Applicators can either be destroyed at the site, shipped to a destruction vendor, 
or returned to Inovio  per instructions provided . If the used I M Applicators are destroyed on 
site, it is the Investigator’s responsibility to ensure that : 
• Arrangements have been made for disposal ; 
• Written authorization has been granted by [CONTACT_343423], Inc., or its 
designee ; RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 31 of 61 
 • Procedures for proper disposal have been established according to a pplicable 
regulation and guidelines and institutional procedures, and ;  
• Appropriate records of the disposal have been documented . 
6.0 CLINICAL TRIAL PROCEDURES AND SCHEDULE  
The Trial Schedule of Events in the Clinical Protocol Synopsis summarizes the trial 
procedures to be performed at each visit. Individual trial procedures are described in detail 
below. It may be necessary to perform these procedures at unscheduled time points if 
deemed clinically necessary by [CONTACT_737]. A participant will be requir ed to provide 
informed consent (Section 6.2) prior to any study procedure being performed. Protocol 
waivers or exemptions will not be granted. Therefore, adherence to the study design and 
assessments are essential and required for study conduct.  
6.[ADDRESS_524944]’s eligibility for 
the study and their ability to comply with protocol requirements by [CONTACT_416575]. Subjects’ post -menopausal status must meet requirements as spe cified in 
the inclusion criteria. The following screening evaluations will be performed within [ADDRESS_524945] fails twice, they will be considered 
a screen failure . 
• Signed and dated informed consent (Section 6.2);  
• Review and confirm all inclusion/exclusion criteria ( Section 4.1 and 4.2 ); 
• Obtain and document complete medical history, surgical history (including all past 
procedures), present conditions and conco mitant illnesses ( Section [IP_ADDRESS] ); document all 
present and/or new or ongoing adverse events prior to administration of IP ; 
• Collect demographics (Section [IP_ADDRESS]);  
• Smoking history (Section [IP_ADDRESS]);  
• Full physical examinations ( Section 6.4.1 ); 
• Record c urrent concomitant medications/treatments ( Section 6.1 3); 
• Record vital signs heart rate (HR), respi[INVESTIGATOR_697] (RR), blood pressure (BP) and body  
temperature ( Section 6.4.2 ); 
• Record body weight, height and determine BMI ( Section 6.4.3 ); 
• Collect blood  for screening laboratory evaluations (Section 6.4. 4); 
• Collect blood for serum pregnancy test , if applicable  (Section 6.4. 4); 
• Collect whole blood and serum for immunology assessment ( Section 6.1 0); 
• Perform laryngoscopy and Staging assessment ( Section  6.4.5 ) prior to surgical removal 
of papi[INVESTIGATOR_81875](s) . 
• Surgical removal of papi[INVESTIGATOR_81875](s)  
• Biopsy tissue (archival slides or blocks) obtained within one year of screening , or during 
surgical removal of papi[INVESTIGATOR_81875](s) will be collected.   
 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 32 of 61 
 Subjects will undergo rout ine procedure for removal of papi[INVESTIGATOR_81875] (s) during the screening 
period , however dosing on Day [ADDRESS_524946] been confirmed , Day 0 dosing may be performed 
the same day immediately following the papi[INVESTIGATOR_416497]. The following assessments 
should be noted at the time of the procedure:  
• Record vital signs heart rate (HR), respi[INVESTIGATOR_697] (RR), blood pressure (BP) and body  
temper ature (Section 6.4.2);  
• Record current concomitant medications/treatments ( Section 6.1 3); 
• Collect  any new adverse events . 
[IP_ADDRESS]  MEDICAL HISTORY  
A medical history will be obtained by [CONTACT_416576]. Medical history will include all active conditions, past conditions,  initial 
diagnosis date, HPV type (if available),  and all prior surgical procedures  and therap ies 
directed toward RRP disease  including adjuvant therapi[INVESTIGATOR_014] , especially those occurring 
within the [ADDRESS_524947] occurring or detected after the signing of the informed consent, or during the study 
and/or worsening of an existing illness in severity, frequency or nature after signi ng of the 
informed consent are to be documented as AEs on the CRF. All prior treatments  should 
be recorded in the CRF as prior medications. Concomitant treatments, defined as 
continuing or new treatments taken at or after the signing of the informed consent, should 
be recorded in the CRF as concomitant medications.  
[IP_ADDRESS]   DEMOGRAPHICS  
Demographic information will be collected via self -report (unless note otherwise), 
including but not limited to age, biological sex and race and ethnicity.  
[IP_ADDRESS]  SMOKING HISTORY  
Smoking history will be collected at Screening via self -report.  
6.1.[ADDRESS_524948]’s Day [ADDRESS_524949] be calculated from Day 0 , unless otherwise noted . All subjects 
will be followed until the Week 52 visit. All subjects will be followed  per assessments 
outlined below . 
[IP_ADDRESS]  Day 0  
The following evaluations will be performed on Day 0  prior to IP administration : 
• Collect all present and/or new or ongoing adverse events;  
• Document any present conditions and concomitant illnesses;  
• Record current concomitant medications/treatments ( Section  6.13); 
• Targeted physical examination ( Section 6.4.1 ); 
• Record vital signs ( Section 6.4.2 ); 
• Record body weight, height and determine BMI ( Section 6.4.3 ); 
• Collect urine for urine pregnancy test, if applicable ( Section 6.4. 4); 
• Collect whole blood and serum for immunology assessment ( Section 6.1 0); RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 33 of 61 
 • Collect safety labs  within [ADDRESS_524950] DLT criteria prior to dosing  (Section 6.4.4 ); 
The following evaluations will be  performed on Day 0  after IP administration : 
• Collect  any new adverse events;  
• Download EP Data (Section 6. 5.1). 
[IP_ADDRESS]  Week 3  
The following evaluations will be performed at this visit  prior to IP 
administration : 
• Collect all present and/or new or ongoing adverse events;  
• Document any present conditions and concomitant illnesses;  
• Record current concomitant medications/treatments ( Section 6.13 ); 
• Targeted physical examination ( Section 6.4.1 ); 
• Record vital signs ( Section 6.4.2 ); 
• Record body weight, height and determine  BMI ( Section 6.4.3 ); 
• Safety labs collected within [ADDRESS_524951] DLT criteria prior to dosing ( Section 6.4.4 ); 
• Collect urine for urine pregnancy test, if applicable ( Section 6.4. 4). 
The following evaluations will be performed after IP administration : 
• Collect  any new adverse events;  
Download EP Data (Section 6. 5.1). 
[IP_ADDRESS]  Week 6 
The following evaluations will be performed prior to IP administration : 
• Collect all present and/or new or ongoing adverse events;  
• Document any present conditions and concomitant illnesses;  
• Record current concomitant medications/ treatments ( Section 6.1 3); 
• Targeted physical examination ( Section 6.4.1 ); 
• Record vital signs ( Section 6.4.2 ); 
• Record body weight, height and determine BMI ( Section 6.4.3 ) 
• Safety labs collected within [ADDRESS_524952] DLT criteria prior to dosing (Section 6.4.4 ). 
• Collect urine for urine pregnancy test, if  applicable ( Section 6.4. 4); 
• Collect whole blood and serum for immunology assessment ( Section 6. 10). 
• Laryngoscopy and Staging assessment ( Section 6.4.5).  
o If it is the Investigator’s practice to routinely biopsy during laryngoscopy, 
this should be performed  at this visit.  
The following evaluations will be performed after IP administration : 
• Collect  any new adverse events;  
• Download EP Data (Section 6. 5.1). 
[IP_ADDRESS]  Week 9 
The following evaluations will be performed prior to IP administration : 
• Collect all present and/or  new or ongoing adverse events;  
• Document any present conditions and concomitant illnesses;  
• Record current concomitant medications/treatments (Section 6.1 3); RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 34 of 61 
 • Targeted physical examination ( Section 6.4.1 ); 
• Record vital signs ( Section 6.4.2 ); 
• Record body weight, height and determine BMI ( Section 6.4.3 ) 
• Safety labs collected within [ADDRESS_524953] DLT criteria prior to dosing (Section 6.4.4 ); 
• Collect urine for urine pregnancy test, if  applicable ( Section 6.4. 4); 
• Collect whole blood and serum for immunology assessment ( Section 6.1 0). 
The following e valuations will be performed after IP administration : 
• Collect  any new adverse events;  
• Download EP Data (Section 6. 5.1). 
[IP_ADDRESS]  Week  11 
The following evaluations will be performed at this visit:  
• Collect all present and/or new or ongoing adverse events;  
• Document any present conditions and concomitant illnesses;  
• Record current concomitant medications/treatments ( Section 6.1 3); 
• Collect whole blood and serum for immunology assessment ( Section 6.1 0); 
• Laryngoscopy and Staging assessment  (Section 6.4.5 ). 
o If it is the Investigator’s practice to routinely biopsy during laryngoscopy, 
this should be performed at this visit.  
[IP_ADDRESS]  Week 26   
The following evaluations will be performed  at this visit:  
• Collect all present and/or new or ongoing adverse events;  
• Document any present conditions and concomitant illnesses;  
• Record current concomitant medications/treatments ( Section 6.1 3); 
• Targeted physical examination ( Section 6.4.1 ); 
• Record vital signs ( Section 6.4.2 ); 
• Collect whole blood and serum for immunology assessment (Section 6.10) ; 
• Laryngoscopy and Staging assessment (Section 6.4.5 ); 
o If it is the Investigator’s practice to routinely biopsy during laryngoscopy, this 
should be performed at these visits.  
[IP_ADDRESS]  Week 52/End of Study visit  
The following evaluations will be performed:  
• Collect all present and/or new or ongoing adverse events;  
• Document any present conditions and concomitant illnesses;  
• Record curr ent concomitant medications/ treatments ( Section 6.1 3); 
• Full physical examinations ( Section 6.4.1 ); 
• Record vital signs (Section 6.4.2) . 
• Collect whole blood and serum for immunology assessment ( Section 6.1 0). 
• Laryngoscopy and Staging assessment ( Section 6.4.5 ). 
• Biopsy  
o Tissue will be sent to the study laboratory for HPV genotypi[INVESTIGATOR_416517] -
assessment  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524954] be in accordance with applicable 
regulations and GCP. Qualified trial personnel will meet with prospective trial participant s, 
explain the trial, and provide them with an informed consent form (ICF) that describes the 
screening tests, eligibility criteria for entering the trial, trial IP and follow -up procedures, in 
a language understandable to the participant . Explanation of the trial includes, but is not 
limited to, trial objectiv es, potential benefits and risks, discomforts/inconveniences, and 
the participant’ s rights and responsibilities. The participant  or participant’ s legally 
acceptable representative is then requested to sign and date the ICF. A copy of the signed 
informed co nsent documentation must be provided to the participant  or participant’ s legally 
acceptable representative. The qualified trial personnel will document the process of 
obtaining informed consent within the source record. Signed ICFs are maintained in the 
participant’ s source records and must be accessible for verification at any time . Signing of 
the ICF begins the screening period . 
6.[ADDRESS_524955] identification number 
(SID), which identifies the participant for all trial -related procedures. SIDs are a 
combination of a four -digit site code and a four -digit participant number starting with 0001. 
Once assigned, SIDs cannot be reused for any reason. Information regar ding the SID and 
screen date will be documented in the eCRF.  
6.4 SAFETY EVALUATIONS  
6.4.1  PHYSICAL EXAM AND TARGETED PHYSICAL ASSESSMENTS  
A full physical examination will be conducted during Screening and at study discharge 
(Week 52 or any other study discontinuatio n visit ). A targeted physical assessment will be 
performed at other visits indicated per schedule of events as determined by [CONTACT_416577].  
6.4.2  VITAL SIGNS 
Vital signs including oral temperature, respi[INVESTIGATOR_1487], blood pressure and heart rate will 
be measured at Screening and all other in -person study visits.  
6.4.3  HEIGHT AND WEIGHT  
Weight (kg ) and height (cm) will be collected at Screening and at each dosing visit in order 
to calculate BMI.  
6.4.[ADDRESS_524956] DLT criteria prior to dosing.  
Approximately 450 mL of blood will be drawn from each participant over the course of the 
study for safety and immunology assessments. A description of the immunology 
assessments can be found in Section 6.1 0.  
 
 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 36 of 61 
 Hematology ( Complete blood count (CBC) with automated diffe rential):  
White blood cell (WBC) count, Red blood cell (RBC) count, hemoglobin, hematocrit and 
platelet count will be measured at Screening, and prior to dos ing at Day 0, Weeks 3, 6, 
and 9. 
• Approximately 2.5 mL of whole blood to be drawn per visit  
Serum ch emistry:  
Electrolytes (Sodium [Na], Potassium [K], Chloride [Cl], Bicarbonate [HCO 3], Calcium [Ca], 
Phosphate [PO 4]), glucose, BUN (blood urea nitrogen), serum bilirubin, alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), and Creatinine (Cr)  will be 
measured at Screening, and prior to dosing at Day 0, Weeks 3, 6, and 9. 
• Approximately 4  mL of whole blood to be drawn per visit  
Pregnancy Testing:  
For women of childbearing potential (WOCBP), a serum pregnancy test will be obtained 
at Screening a nd a urine pregnancy test will be performed prior to each dose . A negative 
result for urine β -HCG (test must have  a sensitivity of at least 25  mIU/mL) must be 
available prior to each administration of IP. If the β -HCG test is positive, indicating that the 
participant is pregnant prior to completing the specified dose regimen, then no further IP 
will be administered. Every attempt should be made to follow pregnant participants for the 
remainder of the study and to determine the outcome of the pregnancy.  
• Approximately 0.[ADDRESS_524957] at 
Screening  
6.4.5  LARYNGOSCOPY AND STAGING ASSESS MENT  
Laryngoscopy will be performed at Screening  (prior to routine removal of papi[INVESTIGATOR_81875](s)) , 
and at Weeks 6, 11, 26, and 52. If it is the Investigator’s practice to routinely biopsy during 
laryngoscopy, this should be performed at these visits. Biopsy will be performed at Week 
52.   
The status of disease will be assessed during each laryngoscopy and an RRP Staging 
Assessment score will be determined using a modified  Derkay staging tool  [34].  Specific 
instructions and guidelines will be provided under separate cover.  
Subjects will undergo surgery  for removal of papi[INVESTIGATOR_81875] (s) during the screening period 
within 14 days prior to  Day 0 dosing (papi[INVESTIGATOR_416495] [ADDRESS_524958] been fulfilled ). 
Status of d isease during the trial will be monitored by [CONTACT_416578].  If at any time during the trial, 
surgical removal (including laser) of papi[INVESTIGATOR_416496], the 
subject may undergo procedure for papi[INVESTIGATOR_416518] .  Documentation of the Staging Assessment score prior to 
surgery is required, and explanation for requirement of surgical removal of papi[INVESTIGATOR_416519].  
Surgical interventions during the t rial must be documented to include at a minimum, 
information about the appearance and location of tissue being removed and instruments 
used. V ideo/  photographic documentation of laryngoscopy is required.  Further instructions 
will be provided under separate  cover.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 37 of 61 
 6.5 INJECTION AND ELECTROPORATION (EP)   
Subjects will receive a four-dose series of INO -3107 by [CONTACT_360800] (or 
anterolateral quadriceps muscle as an alternate option, if deltoid muscle is not possible or 
appropriate) followed immediately by [CONTACT_151678]® [ADDRESS_524959] needle, followed by 
[CONTACT_3450] 10 subjects who will be administered INO -3107 by [CONTACT_416579].   
Study treatment should not be giv en within 2  cm of a tattoo, keloid or hypertrophic scar. If 
there is implanted metal, implanted device, within the same limb then use of the deltoid 
muscle on the same side of the body is excluded.  
6.5.1  DOWNLOADING OF EP DATA FROM CELLECTRA® 2000  DEVICE  
Following each Study IM Administration, data will be downloaded from the 
CELLECTRA® [ADDRESS_524960] information are 
provide d separately. Training will also be provided.  
6.6 MANAGEMENT OF ANXIETY AND PAIN DUE TO ELECTROPORATION (EP)  PROCEDURES  
Participants may  be offered topi[INVESTIGATOR_15413] (e.g., EMLA  or equivalent ) to prevent 
significant discomfort from the injection/EP procedure.  If a topi[INVESTIGATOR_343355], an 
approximate 1.5 cm diameter amount will be applied with occlusion to the administration 
site ~30 minutes prior to injection/EP.   
In case of pain, participant s may be treated with a  non-narcotic  analgesic 
(e.g., acetaminophen ) after injection/EP.  
Participant s who are allergic to or have contraindications to EMLA, acetaminophen, or a 
mild sedative may be offered a suitable alternative . 
Medicat ion taken for pain m anagement will be documented as  concomitant medicati ons. 
6.7 ASSESSMENT OF LABORATORY ABNORMALITIES  
Blood will be drawn for serum chemistry and hematology at the visits listed in  the Schedule 
of Events as listed in Section 6.4. 4.  
Laboratory AEs  will be evaluated based on the Common Terminology Criteria for Adv erse 
Events (CTCAE version 5.0 ). Laboratory values that are not clinically significant (NCS) in 
the Investigator’s  opi[INVESTIGATOR_416520].  
6.8 ASSESSMENT OF CLINICAL TRIAL ADVERSE EVENTS (AE S) 
An adverse event assessment will be conducted at each visit which subjects will be 
queried regarding the occurrence of any adverse events, concomitant medications, new 
onset illness or disease, as well as contraceptive compliance.  Subjects will be reminde d 
to contact [CONTACT_416580]. Adverse events will be captured from the time of the informed consent to 
study discharge. These events will be recorded on the subject’s CRF.  
6.[ADDRESS_524961] 30 minutes after 
each study treatment and at the subsequent study visit following dosing.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524962] appropriate term and use the grading scale as 
listed in CTCAE v5.0. Injection site reactions and administration site pain will be evaluated 
starting 30 minutes following injection/EP  and reported as adverse events on the CRF . 
6.10 PERIPHERAL BLOOD IMMUNOGENICITY ASSESSMENTS  
Whole blood and serum samples will be obtained at baseline (screening and Day 0 prior 
to dosing) and at Weeks 6, 9, 11, 26 and 52.  Details of the immunology sample col lection 
and shipment information will be provided in the Laboratory Manual.  
PBMCs will be isolated from whole blood samples.    
          
 
 
 
 
 
 
         
 
 
 
  
 
 
  
 
 
6.11 HPV-6/11  TESTING  
Historic HPV -6/[ADDRESS_524963]’s eligibility for 
the trial.  If historic results are not available, archival tissue collected during previous 
papi[INVESTIGATOR_416521].    
Archival tissue  (within 1 year of the screening visit) or biopsy tissue collected at screening , 
and tissue collected at Week 52, will undergo  HPV-6/11 testing at a central laboratory.  If 
tissue is resected or biopsied  during the study as clinically indicated, this may also undergo 
HPV-6/[ADDRESS_524964] ion and shipment information will be provided in the Laboratory 
Manual.  
6.12 TISSUE IMMUNOGENICITY ASSESSMENT  
If there is residual tissue in the paraffin block after HPV genotypi[INVESTIGATOR_416522] , Week 52, and as clinically indicated dur ing the course of the study , 
the block or unstained slides prepared from the block will be collected for the a ssessment RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 39 of 61 
 of pro -inflammatory and immunosuppressive elements  and their association with 
treatment success.   
 
 Additional markers may be assessed , and the markers 
listed here may change as new relevant information becomes available.  
  
 
 
 
 
6.13 CONCOMITANT MEDICATIONS /TREATMENTS  
All medications (prescription and nonprescription) taken at the time of Screening and 
ongoing from signing of the informed conse nt to study discharge that do not affect a 
subject’s eligibility for participation (see Section 4.2 ,  Exclusion Criteria) must  be recorded 
on the case report forms (CRFs).  
Actual or estimated start and stop dates must be provided. This information will be 
obtained from the subject and abstracted from any available medical records. The 
indication for the medication, dose, and dose regimen will be documented. Medication that 
is considered necessary for the subject’s safety and well -being may be given at the 
discretion of the Investigator and recorded in the appropriate sections of the CRF . If the 
permissibility of a specific medication/treatment is in questi on, please contact [CONTACT_1034].  
6.14 RESTRICTIONS  
Prohibited Concomitant Medications and Treatments  
The foll owing medications and treatments are prohibited:  
• Long term use (≥ 7 days) of oral or parenteral glucocorticoids at a dose of ≥20 mg/day 
of prednisone equivalent; use of inhaled  (nasal or bronchial),  otic and ophthalmic 
corticosteroids are allowed ; 
• Disease  modifying doses of anti -rheumatic drugs (e.g., azathioprine, 
cyclophosphamide, cyclosporine, methotrexate), and biologic disease modifying drugs 
such as TNF -α inhibitors (e.g. infliximab, adalimumab or etanercept) at screening and 
throughout the study ; 
• Administration of any non -study related, non -live vaccine within 2 weeks of any study 
treatment or within 4 weeks of any study treatment for any non -study, live vaccine  
(prophylactic HPV vaccination , including Gardasil) as attempted therapeutic 
intervention while on -study is not permitted) ; 
• Use of bevacizumab and cidofovir should be stopped at least 3 months prior to Day 0 
visit; 
• Post-surgical course of anti-inflammatory medication and steroids should be avoided.  
Other Restrictions  
Subjects should not use alc ohol or drugs that would interfere with study requirements 
during the course of the study and should report ALL medications/drugs taken to the 
investigator and/or other study personnel.  
Subjects should refrain from becoming pregnant for the duration of the  trial by [CONTACT_416581] (See Inclusion Criteria, Section 4.1).   Lapses in 
contraceptive use should be reported to investigator and/or other study personnel . RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 40 of 61 
 7 EVALUATION OF SAFETY AND MANAGEMENT OF TOXICITY  
7.1 SAFETY PARAMETERS  
The safety of INO-3107 will be measured and graded in accordance with the CTCAE  v5.0. 
7.2 ADVERSE EVENTS (AE S) 
Any untoward medical occurrence in a patient or clinical investigation subject administered 
a pharmaceutical product and which does not necessarily have  to have a causal 
relationship with this treatment.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the use 
of a medicinal product, whether or not considered related to the medicinal product.  
Adverse Events ( AEs) include the following:  
• Pre- or post -treatment complications that occur as a result of protocol mandated 
procedure during or after screening (before the administration of clinical trial drug)  
• Any pre -existing condition , with the exception of the condition under investigation in this 
study,  that increases in severity, or changes in nature during or as a consequence of 
the clinical trial drug administration phase  
• Complications of pregnancy (refer to section 7.11: Reporting Pregnancy  During the 
Clinical Trial)  
Adverse Events ( AEs) do not include the following:  
• Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, transfusion) 
performed; however, the condition that leads to the procedure is an AE  
• Pre-existing dise ases or conditions or laboratory abnormalities present or detected 
before the Screening Visit that do not worsen  
• Recurrences of RRP (disease under study)  
• Situations where an untoward medical occurrence has not occurred (e.g., 
hospi[INVESTIGATOR_390668] s urgery, social and/or convenience admissions)  
• Overdose without clinical sequelae  
• Any medical condition or clinically significant laboratory abnormality with an onset date 
before the ICF is signed, is not an AE; it is considered to be pre -existing and will be 
documented on the medical history CRF  
• Uncomplicated pregnancy  
• An induced elective abortion to terminate a pregnancy without medical reason  
7.3 ADVERSE DRUG REACTION (ADR)  
All noxious and unintended responses to a medicinal product related to any dose. This 
means that a causal relationship between the medicinal product and an adverse event is 
at least a reasonable possibility (i.e., the relationship cannot be ruled out).  
7.4 SERIOUS ADVERSE EVENTS (SAE S) 
An SAE is any untoward medical occurrence that at any dose:  
• Results in death   
• Is life -threatening  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524965] caused death if it 
were more severe.  
• Requires inpatient hospi[INVESTIGATOR_159070]  
o Includes any hospi[INVESTIGATOR_416523], even if the hospi[INVESTIGATOR_151605] a precautionary 
measure to allow continued observation. H owever, hospi[INVESTIGATOR_059] (including 
hospi[INVESTIGATOR_34096]) for a pre -existing condition that has not 
worsened, does not constitute an SAE.  
• Results in persistent or significant disability/incapacity  
o A substantial disruption of a person's ability to conduct normal life functions (i.e., 
the adverse event resulted in a significant, persistent or permanent change, 
impairment, damage or disruption in the subject's body function/structure, physical 
activities and/or quality of life).  
• Results in congenital anomaly or birth defect and/or  
• An important medical event  
o An event that may not be immediately life -threatening or result in death or 
hospi[INVESTIGATOR_416524] s listed above. Examples of such events are 
intensive treatment in an emergency room or at home for allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or 
development of drug dependency or drug abuse.  
Clarification  of Serious Adverse Events (SAEs)  
• Death in itself is not an AE. Death is an outcome of an AE, but when the cause of death 
has not been provided, use the event term: death of unknown cause  
• The subject may not have been receiving an investigational medicinal  product at the 
occurrence of the event  
• Complications that occur during hospi[INVESTIGATOR_98176]. If a complication prolongs the 
hospi[INVESTIGATOR_059], it is an SAE  
7.[ADDRESS_524966] information (e.g., Investigator’s Brochure [IB] for an unapproved investigational 
product, package insert/summary of product characteristics for an approved product) . 
7.6 UNANTICIPATED (SERIOUS ) ADVERSE DEVICE EFFECT (UADE)  
A UADE is  any serious adverse effect on health or safety or any life -threatening problem 
or death caused by, or associated with, a device, if that effect, problem, or death was not 
previously identified in nature, severity, or degree of incidence in the inv estigational plan 
or application (including a supplementary plan or application), or any other unanticipated 
serious problem associated with a device that relates to the rights, safety, or welfare of 
subjects.    
A UADE is a type of SAE that requires report ing to the Sponsor in accordance with secti on 
7.9: Safety Data Reporting Period, Method of Collection and Submission.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 42 of 61 
 7.7 DEVICE DEFICIENCY  
Please refer to Section 7.12 for more information.  
7.8 SAFETY AND TOXICITY MANAGEMENT  
The Medical Monitor is responsible for  the overall safety monitoring of the clinical trial.  
Safety monitoring assessments include but are not limited to:  
• Incidence of all adverse events classified by [CONTACT_9313]  (SOC) , preferred term, 
severity and causal relationship to clinical trial IP administration  
• Changes in laboratory parameters  
• Local and systemic injection site review; special attention will be paid to the examination 
of the injection site  
• Dose Limiting Toxicities (DLT)  
7.8.1  Dose Limiting Toxicity (DLT)  
For the purpose of this clinic al trial, the following are DLTs and are to be reported to the 
Sponsor in accordance with section 7.9: Safety Data Reporting Period, Method of 
Collection and Submission.  
• ≥Grade 3 non -hematological toxicity  (graded per CTCAE v .  5.0 ) that does not respond 
to supportive therapy and lasts for longer than 48 hours   
• ≥Grade 3 hematological toxicity (graded per CTCAE v . 5.0) that does not respond to 
supportive therapy and lasts for longer than 48 hours  
Refer to Section 3.0 for information a bout management of DLTs.  
7.8.2  Abnormal Laboratory Value  
Laboratory results will be evaluated based on the normal ranges and toxicity scale within 
CTCAE v. 5.0 . The PI [INVESTIGATOR_416525] (CS) 
or not clinically signifi cant (NCS).  
Laboratory values that are NCS in the PI’s opi[INVESTIGATOR_416526].  
Any abnormal laboratory value that is new in onset or worsened in severity or frequency 
from the baseline condition and meets one of the following cr iteria will be recorded as an 
AE: 
• Requires therapeutic intervention or diagnostic tests  
• Leads to discontinuation of clinical trial treatment  
• Has accompanying or inducing symptoms or signs  
• Is judged by [CONTACT_978] [INVESTIGATOR_416527] (CS)  
Abnormal laboratory values that meet the criteria of an AE or SAE should be reported in 
accordance with Section 7.9: Safety Data Reporting Period, Method of Collection and 
Submission.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 43 of 61 
 7.8.3  Clinical Trial Stoppi[INVESTIGATOR_416528] p aused until Sponsor discussion with the site 
Investigator determines that enrollment and dosing may continue , if the following CTCAE 
v5.0 events occur  at any time in the study:  
• One Grade 4 or 5 related SAE;  
• Two Grade 3 related SAEs  
7.9 SAFETY DATA REPORTING  PERIOD , METHOD OF COLLECTION AND SUBMISSION  
All AEs will be collected from the time when informed consent is obtained  to Week 52 or 
at participant’s last visit due to early discontinuation . This information will be captured in 
the Electronic Data Capture (EDC) system.  
If the PI [INVESTIGATOR_416529], then the AE will be recorded as an 
SAE.  
SAEs and DLTs  will be reported to the Sponsor from the time the subject signs the 
informed consent until Week 52 or at participant’s last visit d ue to early discontinuation . 
All SAEs (regardless of causal relationship)  and DLTs , will be reported on the SAE Report 
Form and submitted to the Sponsor within [ADDRESS_524967] Information  
Safety Email:  
Safety Fax:  
Safety Phone:   
 
Medical Monitor Direct contact [CONTACT_416582]: Jeffrey Skolnik, M.D.  
Email:  
Cell Phone:   
 
All SAEs , and DLTs must be followed by [CONTACT_978] [INVESTIGATOR_416530], 
or stabilization of the event (i.e.,  the expectation that it will remain chronic), even if it 
extends beyond the clinical trial reporting period.  
Follow -up information is to be submitted to the Sponsor on an SAE Report Form and within 
[ADDRESS_524968]:  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 44 of 61 
 • Redact the medical records of all personal data (e.g., confidential subject data, 
Personal Identifying Information (PII)  
• Provide the assigned clinical trial subject number (SID) on the records  
7.10 ADVERSE EVENT REPORTING  
This section provides details on reporting the safety information.  
7.10.1  Submitting the Initial Serious Adverse Event (SAE) Report Form  
The PI [INVESTIGATOR_416531], but the report must include the following at a minimum:  
• The Adverse Event  
• The subject’s assigned identification (SID) number  
• Investigational product(s) (IP) and/or device  
• Investigator  Causal Relationship to the IP(s) and/or device  
• Serious criteria  
• Reporter name [CONTACT_3669] [CONTACT_416583] a case is submitted to the Sponsor  with only the “minimum” information, a more detailed 
or updated follow -up report will be sent to the Sponsor  as soon as possible but no later 
than three (3)  calendar days after the date of the initial report.  
7.10.2  Recording the Event  
Principal Investigator s (PIs) should use correct medical terminology/concepts when 
recording adverse events on the EDC and Safety Report Form. The use of colloquialisms 
and abbreviations should be avoided.  
A medical diagnosis, if known, should be recorded rather than individual signs and 
symptoms. However, if the signs and/or symptoms cannot be medically characterized as 
a single diagnosis or syndrome, each individual sign and/or symptom should be recorded. 
If a diagnosis is subsequently established, all previously signs and/or symptoms will be 
nullified and replaced with a single medical diagnosis . 
7.10.3  Assessing Severity (Intensity)  
Severity is used to describe the intensity of  a specific event (e.g., mild, moderate, severe).  
The PI [INVESTIGATOR_416532] (based on discussions with clinical trial 
subjects) in accordance with National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE ), v5.0 . 
7.10.4  Causal Relationship of Clinical Material to Adverse Events (AEs)  
A causally related AE is one judged to have a possible, probable or definite relationship 
to the administration of the IP and/or the study device. An AE may also be assessed as 
not related to the IP and/or the study device. Because the PI [INVESTIGATOR_416533] (e.g., medical history, concomitant medications), administers the IP, and monitors 
the subject’s response to the IP, the PI [INVESTIGATOR_416534] a subsequent AE. The PI [INVESTIGATOR_416535]’s clinical state and may have observed the event, and thus may be RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524969] -related.  
Principal Investigators (PIs) should use their knowledge of the clinical trial subject, the 
circumstances surrounding the event, and an evaluation of any potential alternative 
causes to determine whether a n AE is considered to b e related to the IP and/or the study 
device and the causal relationship reported as "Yes" or "No" accordingly. Causality should 
be assessed by [CONTACT_978] [INVESTIGATOR_416536], related to device, or related to both drug and 
device (i.e., re lated to both or indiscernible) by [CONTACT_4868]:  
• Yes - there is a reasonable possibility that administration of the clinical trial treatment 
(drug or device or both drug and device) contributed to the event  
• No - there is no reasonable possibility  that administration of the clinical trial treatment 
contributed to the event and there are more likely causes  
The following guidance should also be taken into consideration:  
• Temporal relationship of event to administration of IP and/or EP  
• Course of the ev ent, considering especially the effects of dose reduction, 
discontinuation of IP, or reintroduction of IP (where applicable)  
• Known association of the event with the IP, EP or with similar treatments  
• Known association of the event with the disease under tri al 
• Presence of risk factors in the clinical trial subject or use of concomitant medications 
known to increase the occurrence of the event  
The rationale for the PI’s causal assessment is to be recorded on the SAE Report Form.  
The Sponsor will assess the ove rall safety of the IP delivered by [CONTACT_416584](ies).  
7.[ADDRESS_524970] administration of clinical trial treatment  
through the study completion (last visit) will be reported to the Sponsor. If clinical trial site 
staff become aware that a subject becomes pregnant after enrolling in the clinical trial, she 
will not be given any additional treatments with the IP. A Pregnancy Form will be 
completed by [CONTACT_978] [INVESTIGATOR_416537] 24 hours after becoming aw are 
of the pregnancy.  
The PI [INVESTIGATOR_416538]/REB/EC in accordance with their policies and 
procedures.  
The clinical trial site must request the subject’s permission to query pregnancy outcome 
and follow the subject for outcome of the pr egnancy. The subject will continue to be 
followed for safety assessments without receiving additional IP until clinical trial discharge 
in accordance with this protocol. Procedures that are contraindicated during pregnancy, 
including additional treatments,  must not be performed. The PI [INVESTIGATOR_416539] -related blood collection based on the 
presence or absence of anemia in each subject.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 46 of 61 
 Male subjects will be instructed through the ICF to immediately inform the  PI [INVESTIGATOR_416540] (last visit) . A Pregnancy Form will be completed 
by [CONTACT_978] [INVESTIGATOR_416537] [ADDRESS_524971] or his pregnant partner, the PI [INVESTIGATOR_416541]/or obstetrician.  
If the end of the pregnancy occurs after the clinical trial has been completed, the outcome 
will be reported directly to the Sponsor.  
7.[ADDRESS_524972] immediately be 
reported to the Sponsor or its designee for evaluation.  
7.13 NOTIFYING REGULATORY AUTHORITIES AND INSTITUTIONAL REVIEW BOARDS 
(IRB S)/ETHICS COMMITTEES (EC S) OF SAFETY INFORMATION  
7.13.1  Sponsor Responsibilities  
• Determine whether the safety information meets the requirements for expedited 
report ing to the applicable regulatory authorities  
• Prepare and submit the safety report to the applicable regulatory authorities  
• Send all participating PIs a safety report and Investigator Safety Letter (i.e.,  Dear 
Investigator Letter ) that will include a statem ent if there is or is not any significant new 
safety information that might influence the risk -benefit assessment of the IP and/or 
study device , sufficient to consider changes in product administration or overall 
conduct of the clinical investigation  
7.13.2  Principal Investigator (PI) Responsibilities  
• Forward a copy of the safety report and Investigator Safety Letter (i.e., Dear 
Investigator Letter) to their IRB/REB/EC as soon as practical in accordance with the 
governing  policy  and/or procedures  
• Notify their  IRB/REB/EC of safety information (i.e., SAEs, pregnancies, etc.) that occur 
at their clinical trial site in accordance with t heir local institutional policy  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524973]-TRIAL REPORTING REQUIREMENTS  
Principal Investigators (PIs) are not obligated to actively seek  AEs or SAEs beyond the 
clinical trial reporting period. However, if the PI [INVESTIGATOR_416542], the PI [INVESTIGATOR_416543] r eport the event to the Sponsor.  
7.15 CLINICAL TRIAL DISCONTINUATION   
The Sponsor  reserves the right to discontinue the clinical trial at this site or at multiple 
sites for safety or administrative reasons at any time. In particular, a clinical trial site that 
does not recruit at a reasonable rate may be discontinued. Additionally, the clinical trial 
may be discontinued at any time by [CONTACT_2717]/REB/EC, the Sponsor , or a regulatory authority 
as part of their duties to ensure  that clinical trial subjects are protected.  
If the clinical trial is discontinued and/or the clinical trial site closed for any reason, an 
Inovio Representative will provide instructions regarding which device components should 
be returned to Inovio Phar maceuticals, Inc., destroyed onsite and/or shipped to a 
destruction vendor. The PI [INVESTIGATOR_416544] (TMF) .  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 48 of 61 
 8 STATISTICAL CONSIDERATIONS  
8.1 STATISTICAL  AND ANALYTICAL PLAN 
The Statistical Analysis Plan is contained in the sections that follow.  
8.2 GENERAL CONSIDERATIONS  
The statistical analysis of the data will be performed b y Inovio Pharmaceuticals or its 
representative.  
This is a single -arm, multi -center clinical trial in subjects with HPV-6- and/or HPV -11-
associated recurrent respi[INVESTIGATOR_28617] (RRP) .  The primary objective is to 
evaluate safety.  The primary endpoint is  safety and tolerability as assessed by 
[CONTACT_416562] (AE) and serious adverse events (SAE).  Secondary efficacy 
analyses include evaluation of frequency of RRP surgical interventions in the year 
following the first dose of investigational product, compared to the frequency in the 
year p rior to  Day 0  dosing , and  changes in RRP Staging Assessment  over time . Other 
secondary analyses concern cellular immunological measures , and tissue 
immunological measures .   
  All safety, efficacy, and immunogenicity data will 
be analyzed separately and combined for patients administered INO -3107 by [CONTACT_416585]. 
8.3 STATISTICAL HYPOTHESES  
No formal statistical hypothesis will be tested in this study.  
8.4 ANALYTICAL POPULATIONS  
The analysis populations will be  the following.  
The intention to treat (ITT) population includes all subjects who are eligible .   
The modified intention to treat (mITT) population includes all subjects wh o receive at least 
one dose of INO -3107 .   
The per -proto col (PP) population comprises subjects who recei ve all doses of INO -[ADDRESS_524974] one do se of INO -3107 . 
8.5 DESCRIPTION OF STATISTICAL METHODS  
8.5.1  Primary  Analyses  
The primary analyses for this trial are safety analyses of Treatment Emergent Adverse 
Events (TEAE) and clinically significant changes in safety laboratory parameters from 
baseline.  
TEAEs are defined for this trial as any AEs that occur following Day 0 following 
administration of study drug (IM + EP), until [ADDRESS_524975] relationship to study treatment.  Multiple occurrences of the same RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524976] to severity and 
relationship to study treatment. All serious TEAEs will also be summarized as above.  
The main summary of safety data will b e based on TEAEs. For this summary, the 
frequency of preferred term events will be calculated along with 95% confidence intervals, 
using the exact method of Clopper -Pearson.  Separate summaries will be based on events 
occurring within [ADDRESS_524977] possible day consistent with 
the partial date.  
AE duration will be calculated as (Stop Date – Start Date) + 1.  
Laboratory response variables will be descriptively summarized per time point and as 
changes from baseline in cluding 95% confidence intervals. Shifts from baseline according 
to the CTCAE will also be presented. Laboratory values considered clinically significant 
will be presented in listings.  
All of the safety analyses will be conducted on the subjects in the saf ety analysis set.  
Analyses will be summarized and presented by [CONTACT_416586] (≤2, 
3-5, and ≥6) and overall.  
8.5.2  Secondary Analyses  
[IP_ADDRESS]     EFFICACY  
The frequency of RRP surgical interventions in the year following the first dose of 
investigational product, compared to the frequency in the year prior to Day 0  dosing , will 
be summarized descriptively  using mean fold -change and a 95% t -distribution -based CI . 
Changes in RRP Staging Assessment  scores from baseline pre-dose  to each post-dose 
evaluation will be analyzed.  Median changes and associated 95% confidence intervals 
will be computed.  
The relationship between the efficacy endpoint versus miRNA results  will be examined.   
Relationships will be examined by [CONTACT_416587], whic h model the endpoint 
outcome versus miRNA results as regressor variables.  
Intersurgical intervals will also be summarized.  
Analyses will be summarized and presented by [CONTACT_416586] (≤2, 
3-5, and ≥6) and overall.  Efficacy analysis  using the mITT population will be conducted. 
The PP population will also be used for a supportive analysis . 
[IP_ADDRESS]     IMMUNOGENICITY  
Increases from baseline in interferon -γ ELISpot and flow response magnitudes will be 
summariz ed.  The median increase s and associated 95% confidence interval s will be 
calculated.  
Changes from baseline in tumor tissue response magnitudes will be summariz ed.  The 
mean increase s and associated 95% t -distribution based confidence interval s will be 
calculated.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524978] treatment 
administration.  
The mITT population will be used for immunogenicity analy ses. 
Analysies will be summarized and presented by [CONTACT_416586] (≤2, 
3-5, and ≥6) and overall . 
8.5.3  Disposition  
Disposition will be summarized and will include the number and percentage eligible , the 
number and percentage who received each dose and the number who completed the trial.  
The number and percentage of subjects who discontinued will be summarized overall and 
by [CONTACT_48933].  The number in each analysis population will also be presented.     
Analysis will be summarized and presented  by [CONTACT_416586] (≤2, 
3-5, and ≥6) and overall . 
 
8.5.4  Demographic and Other Baseline Characteristics  
[IP_ADDRESS]     DEMOGRAPHICS  
Demographic and baseline characteristic data will be summarized with descriptive 
statistics: mean standard dev iation, minimum, median, and maximum values for  
continuous variables, and percentages for categoric al variables , for the ITT population.   
Analysis will be summarized and presented by [CONTACT_416586] (≤2, 
3-5, and ≥6) and overall . 
[IP_ADDRESS]    PRIOR MEDICATION  
Prior medications are those that were used before the start of the trial (prior to Day 0). 
Partial stop dates of prior medications will be assumed to be the latest possible date 
consistent with the partial date; start dates will no t be imputed. Data for all prior 
medications will be summarized with percentages for the mITT population.     
Analyses will be summarized and presented by [CONTACT_416586] (≤2, 
3-5, and ≥6) and overall .  
8.5.5  Interim Analyses   
No formal int erim analyses will be performed for this study.  
8.5.6  Multiplicity  
Not applicable . 
8.5.7  Missing Values  
All analyses will be based upon observed data.   RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 51 of 61 
 8.5.8  Exploratory Analyses  
[IP_ADDRESS]      
 
   
 
 
  
 
 
[IP_ADDRESS]      
 
   
 
 
[IP_ADDRESS]     CONCOMITANT MEDICATION  
Concomitant medications are those used during the course of the tria l (on or after Day 0). 
Partial stop dates of concomitant medications will be assumed to be the latest possible 
date consistent with the partial date; start dates will not be imputed. Data for all 
concomitant medications will b e summarized with percentages , for the mITT population.     
 
Analysis will be summarized and presented by [CONTACT_416586] (≤2, 
3-5, and ≥6) and overall.  
[IP_ADDRESS]    Vital Signs  
Measurements for vital signs as well as changes from baseline will be summarized with 
descriptive statistics: mean, standard deviation, minimum, median, and maximum va lues 
by [CONTACT_7206], for the Safety  population. Baseline is defined as the last measurement prior 
to the first treatment administration.    
 
Analysis will be summarized and presen ted by [CONTACT_416586] (≤2, 
3-5, and ≥6) and overall . 
8.6  SAMPLE SIZE/POWER  
No formal power analysis is applicable to this study, as descriptive statistics will be used 
to summarize the data.  
 
For 30 INO-3107 administered subjects, the trial provides 95% confidence that the true 
incidence of SAEs is < 12% if no SAEs are observed.  
8.7   RANDOMIZATION AND BLINDING  
This is an open -label trial, and therefore, site personnel, individual subjects and INOVIO 
or its representative trial perso nnel will be aware of the treatm ent for this trial.   
Randomization does not apply.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021

INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 52 of 61 
 9 ETHICS  
9.1 INVESTIGATOR  AND SPONSOR RESPONSIBILITIES  
The Investigator and Sponsor are responsible for ensuring that the clinical trial is 
performed in accordance with the protoc ol, the principles of the Declaration of Helsinki, 
Good Clinical Practice (GCP), and applicable regulatory requirements.  
9.[ADDRESS_524979] (IRB)  
The Investigator will undertake the trial after full approval of the protocol and adjunctive 
materials  (e.g., informed consent form, advertising) has been obtained from the 
Institutional Review Board (IRB) and a copy of this approval has been received by [CONTACT_429].  
Investigator responsibilities relevant to the IRB include the following:  
• Submit progress r eports to the IRB as required and request re -review and approval of 
the trial at least once a year during the conduct of the trial.  
• Notify the Sponsor immediately of any suspected unexpected adverse drug or device 
events/effects.  
• Notify the IRB immediately  if the Sponsor notifies the Investigator about any reportable 
safety events.  
• Obtain approval from the IRB for protocol amendments and for revisions to the consent 
form or participant recruitment advertisements, as required.  
• Submit reports on, and reviews of, the trial and its progress to the IRB at intervals 
stipulated in their guidelines and in accordance with pertinent regulations and 
guidelines.  
• Maintain a file of trial -related information (refer to trial files) that includes all 
correspondence with the  IRB. 
• Notify the IRB when the trial is completed (i.e., after the last trial visit of the final trial 
participant).  
• After trial completion (within three [3] months is recommended) provide the IRB with a 
final report on the trial.  
9.3 PROTECTION OF HUMAN SUBJEC TS 
9.3.1  Compliance with Informed Consent Regulations  
Written informed consent is to be obtained from each participant prior to enrollment into 
the trial, and/or from the participant’s legally authorized representative. The process for 
obtaining informed consent  must also be documented in the participant’s medical record. 
(Also refer to section 6.2.)  
9.3.[ADDRESS_524980] (IRB) 
regulations. The Investigator must obta in approval from a properly constituted IRB prior to 
initiating the trial and re -approval or review at least annually. Sponsor is to be notified 
immediately if the responsible IRB has been disqualified or if proceedings leading to 
disqualification have beg un. Copi[INVESTIGATOR_416545].  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 53 of 61 
 9.3.3  Compliance with Good Clinical Practice  
This protocol is to be conducted in accordance with the applicable GCP regulations and 
guidelines.  
9.3.4  Compliance with Electronic R ecords/Signatures Regulations  
When applicable, this trial is to be conducted in compliance with the regulations on 
electronic records and electronic signature.  
9.3.[ADDRESS_524981] be reported to the Medical Monitor 
immediately.  
9.3.6  Changes to the Protocol  
The Investigator should not implement any deviation from or changes to the protocol 
without approval by [CONTACT_416588]/favorable opi[INVESTIGATOR_416546] a protocol amendment, except where necessary to eliminate immediate 
hazards to trial participants, or when the changes involve only logistical or administrative 
aspects of the tr ial (e.g., change in monitors, change of telephone numbers). While every 
effort should be made to avoid protocol deviations, should a deviation be discovered, 
Sponsor must be informed immediately. Any protocol deviation impacting participant 
safety must be  reported to the Medical Monitor immediately.  
9.3.7  Vulnerable Subjects  
This study prohibits the enrollment of subjects who are imprisoned, or compulsory 
detainment (involuntary incarceration) for treatment of either a psychiatric or physical (i.e. 
infectious disease) illness , as well as of children.  
[ADDRESS_524982]’s name /identity  will not be disclosed in 
these documents. The clinical trial Sponsor, its agents, the IRB/REB/EC and regulatory 
authorities will have direct access to the subject ’s medical records for the purposes of trial -
related monitoring, auditing and inspection . Appropriate precautions will be taken to 
maintain confidentiality of medical records and personal information.  
Written Authorization and other documenta tion are to be obtained from each subject , 
and/or from the subject’s legally authorized representative,  prior to enrollment in the  
clinical  trial, in accordance with all applicable laws, regulations and/or directives relating 
to privacy and data protection .  
11 SOURCE DOCUMENTS  
Source data is all information, original records or clinical findings, laboratory results, 
observations, or other activities in a clinical trial necessary for the reconstruction and 
evaluation of the clinical trial. Source data are cont ained in original source documents.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 54 of 61 
 Examples of original  source  documents and data records include:  
• Hospi[INVESTIGATOR_1097]  
• Clinical and office charts  
• Laboratory notes  
• Memoranda  
• Subject’s diaries or evaluation checklists  
• Pharmacy dispensing records  
• Recorded data  from automated instruments  
• Copi[INVESTIGATOR_416547]  (EMR)  certified after verification as being accurate 
and complete  
• Transcriptions certified after verification as being accurate and complete  
• Microfiches  
• Photographic negatives  
• Microfilm or ma gnetic media  
• X-rays 
• Subject files and records kept at the pharmacy, at the laboratories, at the medical records 
facility and within information technology  (IT) systems that are involved in the clinical trial  
The Investigator/institution will permit clinic al trial-related monitoring, audits, IRB/REB/EC 
review and regulatory inspections by [CONTACT_20618]/documents 
related to this  clinical  trial. 
11.[ADDRESS_524983] of the Clinical M onitor, Sponsor or its agent(s), auditor, IRB/REB/EC or 
regulatory authority, the Investigator/institution should make available for direct access all 
requested clinical trial-related records.  
CRFs will be provided for each subject. Subjects must not be identified by [CONTACT_343517]. Subjects will be identified by [CONTACT_343518] (SID).  
It is the Investigator’s responsibility to retain clinical trial essential documents for at least 
two (2) years after the last approval of a marketing application in their country and until 
there are no pending or contemplated marketing applications in their country or at least 
two (2) years have elapsed since the formal discontinuation of clinical development of the 
IP. This retention period may be superseded by [CONTACT_5277]. The Sponso r will 
inform the Investigator/institution when these documents are no longer needed to be 
retained.  
[ADDRESS_524984].   This is a single -arm, open -label 
trial. The Sponsor’s Medical Monitor will have access to unblinded  safety and tolerability 
data during the trial. At a minimum, the Sponsor’s Medical Monitor will review reported 
adverse events quarterly.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 55 of 61 
 12.2  CLINICAL MONITORING  
Clinical Monitoring will be performed by [CONTACT_416589] ’s designee. Records for all clinical trial subjects in this  clinical  
trial will be monitored. The following clinical trial site monitoring tasks will be performed 
at all clinical trial sites:  
• Prior to  subject screening  at the site , a Site Initiation V isit will be conducted to review all 
relevant forms and documentation , and ensure that the clinical trial site staff are  qualified 
and compliant with all applicable requirements  
• All clinical trial site monitoring visits will be documented  
• Periodic clinical trial site visits will be performed throughout the clinical trial 
• The Clinical Monitor will address and document the following  clinical  trial conduct 
activities and obligations:  
o Assure that the  clinical  trial is being conducted in accord ance with the protocol, 
applicable regulatory authority regulations and IRB/REB/EC policies  
o Discuss clinical trial conduct issues and incidents of noncompliance with the 
Investigator and/or  clinical  trial personnel and document them on the Monitoring 
Visit Report . Report any significant unresolved problems immediately to the 
Sponsor  
o Remind the Investigator as necessary of the obligation to immediately report all 
SAEs and DLTs and provide subsequent follow -up report (s) of the final outcome to 
the IRB/REB/EC  
o Throughout the clinical trial, inspect all source documents to ensure  that they are  
Attributable, legible , contemporaneous, original, accurate and complete 
(ALCOA -C) 
o Assure that the clinical trial facilities continue to be acceptable  
o Compare the clinical trial CRFs with source documents to assure that the data are 
accurate and complete and that the protocol is being followed  
o Assure that investigational drug and study device accountability and reconciliation 
of records are complete and accurate  
o Assure that all subject specimens are being stored and forwarded properly for 
testing in accordance with laboratory ma nual requirements  
[ADDRESS_524985] and/or manuscript must be made available to the Sponsor  for 
review and approval in accordance with the governing clinical trial agreement.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 56 of 61 
   RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524986]  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
EMR  Electronic Medical Records  
EP Electroporation  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
GPC  Glycoprotein  
HPV Human Papi[INVESTIGATOR_281778]’s Brochure  
ICF Informed Consent Form  
ICH International Council  on Harmonization  
IM Intramuscular  
IP Investigational Product  
IRB Institutional Review Board  
ISO International Organization for Standardization  
mITT  modified Intent to Treat  
MM Medical Monitor  
mRNA  Messenger RNA  
NCS  Not Clinically Significant  
NHP  Non-human Primates  
pDNA  Plasmid DNA  
PHI Personal Health Information  
PI [INVESTIGATOR_416548]-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.[ADDRESS_524987]  
WBC  White blood cell  
WHO  World Health Organization  
WOCBP  Women of Child bearing Potential  
  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 59 of 61 
 16 REFERENCES  
1. Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, et al. 
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV -
Associated Head and Neck Cancer . Clin Cancer Res 2019; 25(1):110 -124. 
2. Derkay CS, Bluher AE. Update on Recurrent Respi[INVESTIGATOR_416492] . Otolaryngol Clin 
North Am 2019; 52(4):6 69-679. 
3. Major T, Szarka K, Sziklai I, Gergely L, Czeglédy  J. The characteristics of human 
papi[INVESTIGATOR_416549] . J Clin Pathol 2005; 
58(1):51 -55. 
4. Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L. Current and future management of recurrent 
respi[INVESTIGATOR_28617] . Laryngoscope Investig Otolaryngol 2018; 3(1):22 -34. 
5. Omland T, Lie KA, Akre H, Sandlie LE, Jebsen P, Sandvik L, et al. Recurrent respi[INVESTIGATOR_416493]: HPV genotypes and risk of high -grade laryngea l neoplasia . PLoS 
One 2014; 9(6):e99114.  
6. Rosenberg T, Philipsen BB, Mehlum CS, Dyrvig A -K, Wehberg S, Chirilǎ  M, et al. Therapeutic 
Use of the Human Papi[INVESTIGATOR_416550]: A Systematic Review and Meta -Analysis . The Journal of Infectious 
Diseases 2018; 219(7):1016 -1025.  
7. Lin HW, Richmon JD, Emerick KS, de Venecia RK, Zeitels SM, Faquin WC, et al. Malignant 
transformation of a highly aggressive human papi[INVESTIGATOR_61382] 11 -associated 
recurrent respi[INVESTIGATOR_416551] . Am J Otolaryngol 2010; 31(4):[ADDRESS_524988] 2016; 12(11):1176 -1183.  
9. Pai SI, Friedman AD, Franco R, Muniappan A, Park JC, Campbell NP, et  al. A phase II study 
of pembrolizumab for HPV -associated papi[INVESTIGATOR_416552], tracheal, 
and/or pulmonary involvement . Journal of Clinical Oncology 2019; 37(15_suppl):[ADDRESS_524989] HPV6 and HPV11 in mice by [CONTACT_416590] 
E6/E7 antigen . Hum Vaccin Immunother 2012; 8(4):[ADDRESS_524990] 
HPV16/18 generates potent TH1 and cytotoxic cellular immune responses . 
SciTranslMed 2012; 4(155):155ra138.  
12. Aggarwal C, Cohen RB, Morrow MP, et al. Immune Therapy Targeting E6/E7 Oncogenes 
of Human Papi[INVESTIGATOR_133900] 6 (HPV -6) Reduces or Eliminates the Need for  
Surgical Intervention in the Treatment of HPV -6 Associated Recurrent Respi[INVESTIGATOR_416553]. Vaccines 2020; 8(1):E56    
13. Saha R, Killian S, Donofrio RS. DNA vaccines: a mini review . Recent Pat DNA Gene Seq 
2011; 5(2):[ADDRESS_524991] Nile virus is similar despi[INVESTIGATOR_416554] -inserts . Toxicol Sc i 2006; 91(2):[ADDRESS_524992] Nile virus is similar, without integration, despi[INVESTIGATOR_416555] . Toxicol Sci 2006; 91(2):610 -619. 
16. Chattergoon MA, Saulino V, Shames JP, Stein J, Montaner LJ, Weiner DB. Co-immunization 
with plasmid IL -12 generates a strong T -cell memory response in mice . Vaccine 
2004; 22(13 -14):1744 -1750.  RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 60 of 61 
 17. Hanlon L, Argyle D, Bain D, Nicolson L, Dunham S, Golder MC, et al. Feline leukemia virus 
DNA vaccine efficacy is enhanced by [CONTACT_416591] -12 (IL -12) 
and IL -18 expression vectors . JVirol 2001; 75(18):[ADDRESS_524993] a Th1 
phenotype . JInterferon Cytokine Res 1998; 18(7):537 -547. 
19. Kim JJ, Trivedi NN, N ottingham LK, Morrison L, Tsai A, Hu Y, et al. Modulation of amplitude 
and direction of in vivo immune responses by [CONTACT_3252] -administration of cytokine gene 
expression cassettes with DNA immunogens . EurJImmunol 1998; 28(3):[ADDRESS_524994] 
viral infection by [CONTACT_3252] -administration of plasmid DNA coding for viral antigen and 
cytokines in mice . JClinVirol 1999; 13(1 -2):[ADDRESS_524995] of Intramuscular Electroporation for Delivery . Journal of 
Infectious Diseases 2013.  
22. Tebas P, Kraynyak KA, Patel A, Mas low JN, Morrow MP, Sylvester AJ, et al. Intradermal 
SynCon ® Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates 
Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers . J Infect 
Dis 2019.  
23. Tebas P, Roberts CC, Muthumani K, Re uschel EL, Kudchodkar SB, Zaidi FI, et al. Safety 
and Immunogenicity of an Anti -Zika Virus DNA Vaccine - Preliminary Report . N Engl 
J Med 2017.  
24. Morrow MP, Kraynyak KA, Sylvester AJ, Shen X, Amante D, Sakata L, et al. Augmentation 
of cellular and humora l immune responses to HPV16 and HPV18 E6 and E7 antigens 
by [CONTACT_343495] -3100 . Mol Ther Oncolytics 2016; 3:[ZIP_CODE].  
25. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and 
immunogenicity of VGX -3100, a therapeutic synthetic DNA v accine targeting human 
papi[INVESTIGATOR_28597] 16 and 18 E6 and E7 proteins for cervical intraepi[INVESTIGATOR_28601] 
2/3: a randomised, double -blind, placebo -controlled phase 2b trial . Lancet 2015; 
386([ZIP_CODE]):2078 -2088.  
26. Morrow MP, Kraynyak KA, Sylvester AJ, Dalla s M, Knoblock D, Boyer JD, et al. Clinical and 
Immunologic Biomarkers for Histologic Regression of High -Grade Cervical 
Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy . Clin Cancer 
Res 2018; 24(2):276 -294. 
27. Morrow MP, Tebas P, Yan J, Ramir ez L, Slager A, Kraynyak K, et al. Synthetic Consensus 
HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme 
B, Perforin in HIV Infected Individuals . Mol Ther 2015; 23(3):591 -601. 
28. Aihara H, Miyazaki J. Gene transfer into muscle by [CONTACT_316879] . Nat Biotechnol 
1998; 16(9):[ADDRESS_524996] for cell permeabilization . Biochem Biophys 
Res Commun 1999; 261(2):377 -380. 
30. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using 
enhanced delivery of bleomycin by [CONTACT_151638] . Cancer Treat Rev 2003; 
29(5):371 -387. 
31. Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J. Electricall y-assisted nucleic acids 
delivery to tissues in vivo: where do we stand?  Curr Pharm Des 2006; 12(29):[ADDRESS_524997] C, Dean DS, Rols MP. Electrotransfer as a non viral method of gene delivery . 
Curr Gene Ther 2007; 7(1):67 -77. RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
INO-3107    RRP -001 
Inovio Pharmaceuticals, Inc.   Clinical Protocol  
Protocol Version Date: 23Jul2021  CONFIDENTIAL  Protocol Version: 4.0 
 Page 61 of 61 
 33. Diehl MC, Lee JC, D aniels SE, Tebas P, Khan AS, Giffear M, et al. Tolerability of 
intramuscular and intradermal delivery by [CONTACT_360825]( ®) adaptive constant 
current electroporation device in healthy volunteers . Hum Vaccin Immunother 2013; 
9(10):2246 -2252.  
34. Derkay CS, Malis DJ, Zalzal G, Wiatrak BJ, Kashima HK, Coltrera MD. A staging system for 
assessing severity of disease and response to therapy in recurrent respi[INVESTIGATOR_416493] . Laryngoscope 1998; 108(6):935 -937. 
 RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021
Signature [CONTACT_11032]-TMF-[ZIP_CODE] v4.0
Signature [CONTACT_11032]-TMF-[ZIP_CODE] v4.0Reason for signing: Approved Name: [CONTACT_416595]: Approver
Date of signature: 26-Jul-2021 20:11:03 GMT[PHONE_006]RRP-001 Protocol | VV-TMF-[ZIP_CODE] | 4.0
Downloaded on 7/27/2021